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ABSTRACT
Previous research suggests that nucleus basalis 
magnocellularis (NBM) lesions impair cognitive flexibility, 
decrease positive transfer across behavioral problems, and 
impair divided attention. It is unclear, however, whether 
previously observed impairments were due to impaired complex 
relational or "configural learning," or to an impaired 
ability to learn conflicting response rules and apply them 
appropriately as task conditions change. In order to assess 
flexibility in acquiring and using conflicting response
rules, rats with selective lesions of the■NBM or sham-lesion
controls, were subjected to serial reversal training in a 
simple operant discrimination paradigm'. In this paradigm, 
rats were first food-reinforced for lever pressing in 
response to a tone but not reinforced for responding to a 
light. After’ reaching criteria, reinforcement contingencies. 
were reversed and training continued until criteria was 
reached again. Contingencies were reversed a total of four 
times, with training continuing until criteria was reached, 
followed by extinction training.
Based on the argument that the NBM is not involved in 
simple association learning, it was hypothesized that 
acquisition of the original discrimination would not be 
impaired in the NBM lesion group as compared to controls. In
iii
contrast, based on findings suggesting that damage to the 
NBM causes perseveration or causes impairments in cognitive 
flexibility, it was hypothesized that NBM lesions would 
disrupt the ability to efficiently switch between
conflicting response rules. Thus, the NBM lesion group was 
predicted to make more commission errors and to require more 
days to reach criteria on each successive reversal than 
controls. Immediately - following completion of the fourth 
reversal, rats proceeded to an extinction phase. Based on 
the argument that NBM lesions would cause perseveration, it 
was expected that the NBM lesion group would extinguish 
lever press behavior more slowly than controls.. That is, 
when the contingency changed from reinforcement to non­
reinforcement during extinction training, the NBM lesion 
group was expected to continue to respond due to
difficulties changing behavior in response to changes in 
reinforcement contingencies. Results confirm these 
hypotheses. Groups did not differ during acquisition of the 
original discrimination, but the NBM lesion group required 
more days to reach criteria than controls on the first 
reversal. The NBM lesion group, however, demonstrated 
behavioral recovery and subsequent reversal performance did 
not differ between groups. These results suggest that NBM
lesions produce an impairment in cognitive flexibility.
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CHAPTER ONE
ALZHEIMER'S DISEASE
Introduction
Alzheimer's disease (AD) is characterized by a 
degeneration of the cortically projecting cholinergic 
neurons in the nucleus basalis of Meynert in humans (Auld,
Kornecook, Bastianetto, & Quirion, 2002; Braak & Braak,
1996; Chiba, Bucci, Holland, & Gallagher, 1995; Crawley,
1996; Jellinger, & Bancher, 1998; Lowes-Hummel, Gertz,
Ferszt, & Cervos-Navarro, 1989; Muir, 1997; Nitsch, 1996;
Perl, 2000; Samuel, Terry, DeTeresa, Butters, & Masliah,
1994; Sarter & Bruno, 1999; Wenk, 1997; Whitehouse, Price, 
Clark, Coyle, & Delong, 1981; Winkler, Thai, Gage, & Fisher, 
1998). This neurodegeneration leads to both a decreased 
amount of the neurotransmitter acetylcholine (ACh) in the 
neocortex and decreased cognitive functioning. AD is the 
leading cause of dementia in mid to late adult life, leading 
to memory loss, decline in ability to perform routine tasks, 
disorientation, difficulty in learning, loss of language 
skills, impairment of judgment and personality changes 
(Alzheimer's Association; Auld et al., 2002; Wenk, 1997).
It is the significant loss of brain cells that ultimately
1
leads to body system failure and ultimately death (Dickson,
2001) .
According to the Alzheimer's Association (www.alz.orq),
about 4.5 million Americans, suffer from AD. In a 1993
national survey, 19 million Americans were found to have a 
family member with AD, and 37 million knew someone with AD. 
Another startling statistic is that 14 million Americans
will have AD by the middle of the next century unless a cure 
or prevention is found. AD is also an expensive disease to 
treat, with the average lifetime cost being approximately
$174,000.
Cognitive Impairments in Alzheimer's Disease 
The progression of AD usually follows a pattern,
beginning with memory dysfunction; the first signs of AD are 
usually problems associated with memory. Other 
presentations of the disease include personality changes, 
visuospatial disorientation, difficulty with language, and 
even depression. The disease process then leads to motor 
problems until the patient is unable to get out of bed, no 
longer speaks, is incontinent, and becomes completely 
disoriented (Braak et al., 1996; Dickson, 2001).
In the midst of other cognitive and physical changes, 
memory impairments remain constant throughout the
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progression of the disease (Eslinger & Damasio, 1986; Spaan, 
Raaijmakers, & Jonker, 2003). Patients with AD suffer a 
myriad of memory impairments which include difficulty with 
free recall (Eslinger & Damasio, 1986; Martin, Brouwers,
Cox, & Fedio, 1985), cued recall (Bird & Luszcz, 1991; Bondi 
& Kaszniak, 1991; Chertkow & Bub, 1990; Monti, Gabrieli, 
Reminger, Rinaldi, Wilson, & Fleischman, 1996; Russo & 
Spinnler, 1994), as well as impaired recognition memory 
(Dudas, Berrior, & Hodges, • 2005; Eslinger & Damasio, 1986).
Memory impairments usually affect one's ability to 
learn new things. However, certain types, of learning are 
spared in AD. Eslinger and Damasio (1986) compared AD 
patients with controls on motor, verbal, and visual learning 
tasks and found that despite difficulty in learning both 
verbal and nonverbal information, AD patients were able to 
learn motor activities that required procedural memory. 
Procedural memory or skill learning, involves implicit 
memory. This type of memory involves multiple cognitive 
functions as well as motor skills to practice the new skill 
until it becomes habit. If procedural memory is intact, the 
individual can improve his or her performance of the task on 
subsequent trials. This is in contrast to declarative 
memory or knowledge which is dependent on memory which may 
be context specific and relate to specific experiences with
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objects or places (e.g. facts, or events). Declarative 
memory, which involves memory of sensory experiences and is 
usually contextual, can be further divided into episodic and 
semantic memory (Eslinger & Damasio, 1986). Semantic memory
refers to facts and general knowledge while episodic memory 
refers to our experiences. -Impairments in both of these 
types of memory can be found in early stages of AD (Dudas et 
al., 2005; Spaan et al., 2003). In the same study, during 
the motor learning task, which required procedural memory,
AD patients were initially impaired but improved with 
subsequent trials. However, the AD group failed to learn 
both the verbal and visual learning tasks which were 
examples of tasks that required declarative memory.
According to Dudas et al. (2005), at this early stage 
of the disease the patient is customarily diagnosed with
mild cognitive impairment (MCI). Dudas et al. (2005) found 
that patients with MCI as well as those with AD, show signs 
of episodic and semantic memory loss. Approximately 15-20% 
of patients diagnosed with MCI are diagnosed with AD-within 
a 2 year period of their initial diagnosis. Consequently,
because of the increased risk of a person diagnosed with MCI 
to be later diagnosed as having AD, early’ detection of these 
impairments is critical.-
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These types of cognitive impairments are usually the 
first to be reported and are common even before the patient 
is presumed to have AD. Impairments in free recall, cued 
recall, and recognition are all examples of episodic memory 
impairments. According to Spaan et al., (2003), this 
suggests that individuals with AD experience a general 
episodic memory impairmentt Others argue that instead of a 
general episodic memory impairment, it is faulty encoding 
that prompts the learning impairments seen in AD (Greene, 
Baddeley, & Hodges 1996). Still, others argue that episodic 
memory is dependent on semantic memory (Dudas et al., 2005).
Another type of memory impairment in AD patients 
involves working memory or memory span. Rochon and 
colleagues (2000) compared performance of AD patients with . 
age matched controls on a series of working memory tests and 
sentence comprehension. AD patients were found to have 
reduced memory spans compared to controls as well as 
difficulty with sentence comprehension. Additionally, there 
is evidence suggesting a visuospatial working memory 
impairment in patients with AD (Trojano, Chiacchio, De Luca, 
& Grossi, 1994).
Johnstone et al. (2002) have provided a profile of the 
neuropsychological deficit seen in AD dementia. In 
evaluating the.degree of deficit, the authors examined five
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areas of performance in cognition and compared them to an 
estimate of premorbid intelligence in order to calculate the 
relative degree of decline. The five areas examined were: 
intelligence, memory, attention, speed of processing and 
cognitive flexibility. Subjects were given various
standardized tests such as the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R), the Wechsler Memory Scale-Revised 
(WMS-R), the Wide Range Achievement Test-Revised (WRAT-R), 
the Reading Subject Test and the Trail Making Tests.
Results of this study indicate that speed of processing and 
cognitive flexibility suffered the most in AD patients.
Perseveration in Alzheimer's Disease
Bigler et al. (1988) note that AD patients have 
difficulty changing behavior in the face of changes in 
reinforcement contingencies. This is what is referred to as 
perseveration. Although there are different types of 
perseveration, perseveration generally reveals itself as 
inappropriate persistent responding such that the person or 
animal repeats or fails to inhibit a previous response 
(Bayles, Tomoeda, McKnight, Helm-Estabrooks, & Hawley 2004; 
Galdi, 1993). Normal humans treated with drugs that 
interfere with the neurotransmitter ACh show perseveration,
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suggesting a link between cholinergic dysfunction and 
perseverative behavior (Bigler et al., 1988).
Patients with AD show signs of verbal and nonverbal
perseverations. These examples of cognitive inflexibility
or rigidity have been further divided into more specific
types of perseveration such as continuous, recurrent,
substitution, and stuck-in-set perseveration (Bayles et al.,
2004; Ryan, McGowan, McCaffrey, Ryan, Zandi, & Brannigan,
1995; Lamar., Carew, Resh, Goldberg, Podell, & Cloud e't al.,
1997; Caccappolo-van Vliet, .Miozzo, Marder, & Stern, 2003).
Continuous perseveration refers to the act of continuing to
respond in the same manner without any interruptions.
Recurrent perseveration is responding to a new stimulus as-
if it were the previous stimulus. Substitution
perseveration refers to replacing one object or element of a 
✓ •
task with another. Finally, -stuck-in-set perseveration 
refers to the inability to shift- -from one method of 
responding to another. (Caccappolo-van Vliet et al., 2003;. 
Lamar' et al. , 1997; McNamara & Albert, 2004; Ryan et'al., 
1995; Sandson & Albert, 1984). , . .
In a case study and review of perseveration, 
Caccappolo-van Vliet et al. (2003-) discussed the hypothesis 
that damage to specific brain areas result, in specific types 
of perseveration. This hypothesis had previously been
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supported by Sandson and Albert (1984) who found that stuck-
in-set perseverations were a result of frontal lobe damage. 
The subject in the Caccappolo-van Vliet et al's. (2003) 
study exhibited continuous perseverations which have 
previously been attributed to an impairment in attention. 
However, Caccappolo-van Vliet and colleagues (2003) do not 
attribute their subject's perseverations to a general 
impairment in attention because the perseverations were only 
limited to writing. In contrast, perseverations that are 
due to an impairment in attention usually result in 
perseverative errors in a wide assortment of tasks.
In a study of AD patients and verbal perseveration 
(Bayles et al., 2004), a significant relationship was found 
between results of attention and memory tests, mental status 
and task type. The patterns and amount of verbal
perseverations observed in the AD patients depend on type of 
test, mental status, attention or memory tests. Bayles et 
al. (2004) hypothesized that AD patents would perseverate
more than controls on language tests and that the amount of 
perseveration would vary according to type of language test, 
mental status, and performance on various attention and 
memory tests. Subjects were given two of three different 
language tests which were all a variation of a naming test 
(Confrontation Naming, Generative Naming, and Picture
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Description). Mental status was measured’ using the Mini-
Mental State Exam (MMSE). Attention and memory tests 
included the Modified Wisconsin Card Sort, the Wechsler 
Memory-Scale-Revised and the Arizona Battery for
Communication Disorders, in Dementia.
Overall, Bayles et al. (2004) found that AD patients 
did indeed perseverate more than controls. However, the 
amount of perseveration varied according to task type, with 
significant differences found between groups on the 
Generative Naming test. Puzzlingly, a positive correlation 
was found between mental status and amount of perseveration 
on the Generative Naming test; with relatively better mental 
status, AD patients tended to perseverate more on this task. 
The other two language tests were negatively correlated with 
amount of perseveration.
According to Bayles et al. (2004), results of this
study are more complex than might first be apparent. 
Considering that mental status and cognitive impairment, in 
terms of amount of perseveration, do not necessarily follow 
a linear .pattern, a more complex argument must be 
investigated. Bayles et al. (2004) suggest that the varying 
results of this study may reflect differences in the 
relative cognitive demand linked to each assessment 
instrument. It may be that the absence of perseveration is
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a result of too difficult a task, meaning that if the 
patient could have done the task then perseverative behavior 
might have been witnessed.
Alzheimer's disease is not the only form of dementia 
that results in perseverative behavior. Patients suffering 
from ischemic vascular dementia (IVD) also show signs of 
perseveration. However, the patterns and types of
perseverations vary according to the type of dementia (Lamar 
et al., 1997). One theory to explain these differences 
involves a ranking of cognitive disorders that are related 
to different types of perseveration. What this means is 
that higher level cognitive disorders lead to perseverations 
of higher order semantic functions and lower level cognitive 
disorders are related to perseverations of lower level 
functions such as motor behaviors (Lamar et al., 1997; 
Goldberg, 1986) . This hypothesis is supported by Lamar and 
colleagues (1997) who compared perseverative behavior of AD 
patients with IVD patients. In'this study, perseverations 
made by AD patients were of a higher order cognitive nature 
whereas IVD patients made more motor related perseverations.
Ryan et al. (1995) examined perseveration in a group 
of Alzheimer's patients. Specifically, they studied 
"wandering," a type of nonverbal perseveration, which is 
defined by increased motor activity and frequent
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disorientation in familiar places. It'was predicted that .AD 
patients with wandering behavior would be more likely to 
perseverate on a series of cognitive tasks (e.g.,' Bender 
Visual Motor Gestalt, the Clock Drawing Test, and the 
Attention/Concentration Index taken from the WMS-R) compared 
to AD patients without wandering .behavior. Dependent 
measures were type and amount of perseveration,
attention/concentration, and spatial orientation for each of 
the following tasks. The.Bender Visual Motor Gestalt 
identified three types of perseveration: 1) continuous 
perseveration, 2) recurrent perseveration, and 3)
substitution perseveration-.
Results indicate that AD patients that exhibited
I
"wandering" behavior were more likely to also display 
recurrent and continuous perseverations in the Bender Visual 
Motor Gestalt test when compared to non-wandering AD
■ f __patients. AD patients with "wandering" behavior that were 
also identified as having multi-in'farct dementia were more 
likely to show substition perseverations. Substitution 
perseverations are believed to be linked to encephalopathy, 
and frontal or frontotemporal damage. Continuous ' 
perseverations are said to be linked to right hemispheric 
damage, which may result in. impairments in attention and 
even locomotor activity. Surprisingly, there were no
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significant differences in visuospatial skills between . 
wanderers and patients who did not show signs of wandering 
behavior. Ryan et al. (1995) suggest that the link between
visuospatial skills and wandering behavior may not be 
clearly evident until the mid to late stages of AD.
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CHAPTER TWO
NEUROANATOMY AND NEUROPATHOLOGY
Introduction
Classification of AD is a combination of both
macroscopic and microscopic changes. Macroscopic changes 
primarily involve cerebral atrophy. Microscopic changes 
include neurofibrillary tangles, senile plaques, congophilic 
angiopathy, granulovacuolar bodies, hirano bodies, and
synaptic loss (Perl, 2000). Postmortem evaluation of AD 
brains reveals dilated lateral ventricles and atrophy of the 
hippocampus and amygdala. Other changes include loss of, 
pigment to the locus ceruleus,-loss of large pyramidal 
neurons in the cortex, significant synaptic damage, amyloid 
plaques, 'neurofibrillary tangles and neurophil threads. 
Granulovacuolar degeneration and Hirano bodies are also 
found in AD brains, as well as normal brains, much to a 
greater degree. Research has also been able to link 
cognitive impairment with the amount of granulovacuolar 
damage as well as neurofibrillary tangles, neurophil 
threads, and extent of synaptic injury (Dickson, 2001).
Various organizations have also identified criteria by
which AD can be identified. These criteria include a scale
based on number of senile plaques, density of senile
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plaques, as well as an evaluation of extent of damage by 
neurofibrillary tangles in conjunction with Braak and Braak 
stages (Perl, 2000) .
According to Jellinger et al. (1998), in order to 
receive' a diagnosis of AD, postmortem examination of the 
brain looks for the presence of the following: atrophy of 
the cerebral cortex, neuritic plaques, neurofibrillary 
tangles, neurophil threads, paired helical filaments, 
amyloid plaques and angiopathy. There is also damage to 
cortical connections that ultimately lead to the symptoms of 
dementia. It is these interruptions in synaptic connections 
that are most responsible for cognitive deterioration seen
in AD.
There are also many statistical analyses that can be 
done to evaluate the relationship between physical findings 
and cognitive impairments. For example, examination of 
postmortem AD brains found that synaptic density in the 
midfrontal cortex was a predictor of cognitive impairment 
(Samuel et al., 1994). There are also various cognitive
tests such as the Mini-Mental state or criteria to determine
the stages of AD. Other statistically reliable analyses 
take into consideration the number of neurofibrillary 
tangles in the association neocortex (Dickson, 2001;
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Doucette, Fisman-, Hachinski, & Mersky, 1986; Jellinger et
al., 1998) .
To summarize, Alzheimer's disease . (AD) is characterized 
by specific neuropathology that includes amyloid plaques and 
neurofibrillary tangles throughout .the neocortex, and 
significant cholinergic neuron death in the nucleus basalis 
of Meynert (AUld et al., 2002; Cummings, & Back, 1998; 
Doucette et al., 1986; Etienne, Robitaille, Gauthier, &
Nair, 1986; Ezrin-Waters & Resch, 1986; Francis et al.,
1999; Jellinger et al., 1998; Lahiri, Farlow, Sambamurti, 
Greig, Giacobini, & Schneider, 2003;.Mann, 1985; Pearson, 
Esiri, Hiorns, Wilcock & Powell, 1985; Pepeu et al., 1994; 
Rogers, Brogan, & Mirra, 1985; Samuel et al., 1994; Sarter & 
Bruno, 1999; Strada et al., 1992; Winkler et al., 1998).
Each of these major forms of neuropathology will be revealed
below.
Amyloid Plaques and Neurofibrillary'Tangles 
According to Braak and Braak (1996) amyloid deposits
form before the formation of neurofibrillary tangles (NFT). 
The presence of both features-is representative'of later ■ 
stages of AD. Neurofibrillary changes usually affect the 
hemispheres in a symmetrical fashion but neuritic plaques, 
such as beta amyloid (A3) plaques, are not usually found in
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a uniform distribution. Other lesions found in AD brains
include neurophil threads in the cortex, where their 
densities are usually correlated with NFT’ density.
NFT's are intracellular structures that are made up of 
filaments that consist of a microtubule-associated protein, 
tau. The amount of NFT throughout the brain in areas 
including the cortex, temporal neocortex, and
parahippocampal gyrus, has been correlated with the extent 
of cognitive impairments found in AD (Lahiri et al., 2003; 
Larner, 2002). NFT measures have been found to be better
predictors of cognitive deficits than A(3 plaques. As a 
result, inhibition of tau represents a possible intervention 
for AD patients. Drugs that work on tau have two main foci, 
either to block the hyperphosphorylation of tau or to 
inhibit the kinase that phosphorylates tau (Larner, 2002).
There is evidence demonstrating a genetic component to 
the abnormal amyloid protein responsible for amyloid plaque
accumulation in AD. In a review of AD and the treatments of
AD, Cutler et al., (2001) noted that as much as 30-50% of AD 
cases could be linked to genes. For instance, mutations of 
amyloid precursor protein (APP) have been associated with 
familial AD. Research has suggested that APP is a
significant factor in the pathology of AD (Cutler et al., 
2001; Lahiri et al., 2003). Specific genes of APP,
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pr.esenilin 1 (PS-1) and presenilin 2 (PS-2), have been
suggested to be responsible for familial AD‘as well as the 
production of amyloid plaques, thus leading to an amyloid 
hypothesis of AD.. As a result, much of AD research has 
focused on the inhibition of A(3 production. To study this 
hypothesis, researchers have created transgenic mice that
carry mutated forms of the human APP genes. Because A(3 
production Involves various secretases, specifically a, (3 
and ysecretase, it is logical that research in this area 
has focused on the enzymes that act on APP and thereby 
result in the production of A3 plaques. PS-1 knockout 
mice have shown a prominent decrease in y-secretase activity 
but no change in activity of the other two secretases.
Thus, y-secretase activity has recently developed a 
significant amount of attention (Larner, 2002).
The release of APP has also been found to be activity- 
dependent. This was confirmed by generating action 
potentials in rat brain tissue slices, which increased the
release of various neurotransmitters. Electrical
depolarization then resulted in the release of APP's but not 
other proteins subsequently eliminating the possibility that 
the increase of APP's was due to other factors, such as 
leakage. Further research also suggests that APP's have 
neuroprotective properties related to learning and memory,
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but this hypothesis calls for additional research.. In 
contrast, research in genetics has found that APP's are 
involved in the production of A3 peptides, which are
neurotoxic. AD brains have also been found to have a
greater number of receptors for A3 peptides than controls
(Dickson, 2001; Nitsch, 1996).
Potential treatments to suppress production of amyloid 
plaques involve the use of muscarinic ml receptor agonists. 
Preliminary studies have found that muscarinic agonists have 
the ability to impede the progression of APP's as well as 
delay the disease process of AD and improve attention. The 
potential ability for muscarinic agonists to increase levels 
of. APP derivatives, such as p3, and its impact on the 
progression of AD is still under investigation (Nitsch,
1996) .
Another target of treatment of AD is A3 neurotoxicity. 
Treatment such as vitamin E and other antioxidants have had
some success in delaying the progression of AD. Other 
treatment strategies have focused on researching a possible 
AD vaccine. This vaccine consists of A3 antibodies and has 
successfully decreased the amount of A3 plaques (Larner, 
2002).
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Cholinergic Hypofunction in Alzheimer's Disease 
Another important finding associated with AD is the
significant neuronal loss in the nucleus basalis of Meynert 
(nbM). This loss of neurons is indicative of the damage to 
the basal forebrain cholinergic system and has shown to be 
correlated with the severity of cognitive deficits (Auld et
al., 2002; Cummings et al., 1998; Doucette et al., 1986;
Etienne et al., 1986; Ezrin-Waters et al.,1986;. Francis et 
al., 1999; Gold, 2003; Jellinger et al., 1998; Larner, 2002; 
Mann, 1985; Pepeu et al., 1994; Rogers et al., 1985; Samuel
et al., 1994; Strada et al., 1992; Wenk, 1997; Winkler et
al. , 1998) .
Another important characteristic of the nbM is related
to its location in the brain. The nbM is located in the
basal forebrain, specifically in the substantia innominata 
(Ezrin-Waters et al., 1986; Wenk, 1997). The nbM is
centrally located between the structures of the limbic 
system and the neocortex. In addition to providing the 
cortex with ACh, the nbM also receives input from the limbic 
system and then relays information to the neocortex. This 
anatomical evidence may provide insight to some of the 
psychiatric symptoms of AD (Auld et al., 2002; Cummings et 
al., 1998) .
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The neurons of the nbM project to many areas of the 
brain including the hypothalamus, amygdala and. the cortex.
As previously mentioned, the significant cell loss in the 
nbM affects a number of neurotransmitter systems. The
cortical projections of the nbM are the most relevant to 
this study because they supply the cortex with ACh and a
substantial loss of cortical ACh is another common feature
of AD patients (Ezrin-Waters et al., 1986; Francis et al., 
1999). This decrease in cortical ACh in AD patients has led 
to the development of the cholinergic hypothesis- of AD.
This hypothesis suggests that the cognitive dysfunction
found in AD can be attributed to the loss of neurons in the
nbM which results in less ACh distributed to the cortex
(Auld et al., 2002; Bartus, 2000; Cummings et al., 1998; 
Lahiri et al., 2003; Sarter, 1994; Terry et al. 2003). 
Additionally, support for this hypothesis is that the 
current and most effective treatments for AD are cholinergic 
drugs (Auld et al., 2002; Cutler et al., 2001).
Samuel et al. (1994) examined plaques, neurofibrillary 
tangles, neuronal and synaptic density in the nucleus 
basalis of. Meynert (nbM) of probable Alzheimer's disease 
(AD) patients postmortem. Participants in this study also 
underwent extensive neuropsychological tests prior to death. 
Tests included the Blessed Information-Memory-Concentration
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(IMC), the Mini-Mental State Examination (MMSE), and the
Dementia Rating Scale (DRS). Severity of dementia was 
correlated with the degree of neuropathology in cortical and 
subcortical brain regions, especially in the nbM.- Results 
of this study suggest that two important contributors to 
dementia found in AD patients. Samuel et al. (1994) found 
that diminishing synaptic- density in the midfrontal cortex 
was highly correlated with severity of dementia. In the . 
nbM, -neurofibrillary tangles were found to be most
predictive of dementia, correlating significantly with 
degree of cognitive impairment.
Doucette and colleagues (1986) found significant 
differences in neuronal loss in the nbM related to severity 
of AD dementia. Patients who exhibited severe cognitive 
impairments, as determined by the Extended Scale for 
Dementia (ESD) , also possessed a greater degree of neuronal 
loss in the intermediate and posterior regions of the nbM 
compared to AD patients with less severe cognitive
dysfunction. Other studies have demonstrated severe nbM 
cell loss via postmortem evaluation of AD brains where there 
can be as much as 90% cell loss in the nbM (Doucette et al., 
1986; Ezrin-Waters et al., 1986;).
McGeer et al. (1984) evaluated age-related changes in 
the nbM and found cholinergic cell counts as low as 45,500-
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100,500 in AD brains compared to 140,000 in non-AD brains of 
human subjects 80 years of older. These changes are 
remarkable when compared to younger controls in the study 
who had as much as 400,000-475,000 cholinergic cells.in the 
nbM. Additionally, age-dependent neuronal loss in the nbM
has been found in humans (Lowes-Hummel et al., 1989).
Further evidence suggesting a connection'between the 
cholinergic system and the disease process of AD involves 
choline acetyltransferase (ChAT). A significant loss of nbM 
neurons results in decreased ChAT activity. Previous 
research has found that pre-mortem mental test scores of AD 
patients is associated with ChAT'activity. Reductions in 
ChAT activity in AD patients can be quite dramatic. For
example, previous biochemical research has found 30-90% 
region specific reductions in ChAT activity. As much as a 
50% decrease in mRNA ChAT activity has also been found in 
the frontal, parietal, and temporal cortices' of AD patients. 
Other related factors include high affinity choline uptake
(HACU), ACh release and both nicotinic and muscarinic ACh
receptor binding. Later stages of AD, and therefore severe 
cognitive deficits, are also associated with severe 
decreases in CHAT activity (Auld et al., 2002).
Damage to the cholinergic neurons of the basal 
forebrain of AD' patients not only affects ChAT activity and
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ACh release but it also affects cognition. There is a 
substantial amount of evidence to support a relationship 
between cognitive processes and the cholinergic system. For 
example, cortical ACh has been shown to be associated with 
various forms of attention as well as learning and memory 
(Gold, 2003; Sarter, & Bruno, 1994; Sarter, & Bruno, 1999; 
Sarter, Bruno & Givens, 2003). Attention related problems 
such as increased response latencies, decreased response 
accuracy, impairments in perceiving information and divided 
attention are found in patients diagnosed with senile
dementia (Sarter, 1994) .
Sarter (1994; Sarter, & Bruno, 1999) suggest that ACh 
plays a major role in the processing of stimuli. For 
example, research has shown that corticopetal cholinergic 
projections, and therefore ACh, is involved in the 
detection, selection, and processing of various stimuli as 
well as associations (Sarter & Bruno, 1999; Sarter, Bruno, & 
Turchi, 1999) . Additionally, previous research has found 
strong correlations between the degree of cortical 
cholinergic neuron damage and the ability to detect, select 
and process behaviorally relevant stimuli. Studies 
involving humans and muscarinic antagonists, such as 
scopolamine, also support this hypothesis (Sarter & Bruno,
1999).
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Other psychiatric disorders marked by cognitive 
impairments also possess features of a dysfunctional 
cholinergic system. According to the cholinergic 
hypothesis, the cognitive symptoms of AD and other dementias
may be due in part to cholinergic hypofunction and
additionally cholinergic hypofunction may trigger the 
cognitive deficits found in schizophrenia (Sarter, 1994). 
Sarter and Bruno (1999) also suggest that .the cumulative 
effects of inappropriate processing by the cholinergic 
system leads to the attentional impairments seen in many 
neuropsychiatric disorders.
ACh has been shown to possess a significant role in 
processing throughout the sensory,' somatosensory, and 
associational areas of the cortex. In the visual cortex,
research has revealed that ACh assists neurons in their
ability to respond to visual stimulation as well as process
visual information. Evidence comes from an increase in
responsivity of cortical neurons that stem from the lateral 
geniculate nucleus as well as animal lesion studies.
Lesions of the basal forebrain resulted in decreased
responsivity to visual stimulation. In humans,
administration of muscarinic receptor antagonists such as 
scopolamine resulted in decreased ability to perform 
visuospatial tasks such as line orientation. In addition,
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patients suffering from senile dementia also display visual 
impairments possibly related to loss of cortical cholinergic 
inputs to the visual cortex. In the auditory cortex, ACh
increases the activation of neurons. This ACh evoked
increase in activation is hypothesized to ease the
recognition and discrimination of tones (Sarter, & Bruno,
1997).
Studies involving administration of cholinesterase 
inhibitors have also yielded significant results in sensory 
cortices. These drugs have demonstrated the influence of 
ACh on receptive fields of cortical sensory neurons as well 
as the ability of ACh to alter neuronal responding. As 
previously shown in the auditory cortex, ACh is also 
responsible for increases in activation of neurons in the 
somatosensory cortex (Sarter & Bruno, 1997), as well as
changes in the reactivity of cortical neurons (Sarter,
1994). Specifically, research shows that ACh is involved in 
sensory plasticity. For example, ACh'has been found to be 
involved in the organization as well as changes to the - 
receptive fields of the somatosensory cortex (Sarter, 1994; 
Sarter & Bruno, 1997). According to Sarter (1994), these 
changes take place as a result of ACh's ability to assist in 
the processing of stimuli deep within the somatosensory 
cortex. These changes are reflected as enduring yet
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adaptable changes (Sarter, & Bruno, 1997) . Additional 
evidence of the influence of ACh on neuronal plasticity will
be discussed later.
One hypothesis is that the role of ACh, in regards to., 
processing of relevant stimuli, is related to the cognitive 
concept of attention. Previous research suggests that 
changes in cortical ACh release■are related to level of 
cognitive demand or required.attention. Thus, cholinergic 
cell loss results in cognitive impairments affecting
attention (Sarter, & Bruno, .1997). However, it should be
noted that ACh is not tlhe only neurotransmitter that may be 
involved in this aspect of cognition.
Other Neurotransmitter- System Involvement
Other neurotransmitter systems interact with the 
cholinergic system, including the Y_Amino butyric acid 
(GABA) system. The GABA system is closely linked to the 
cholinergic system and therefore is also important to the 
study of AD. Cholinergic neurons of the basal forebrain 
receive GABAergic input from the nucleus accumbens (Sarter &
Bruno, 1994; Sarter, Bruno, & Turchi, 1999; Sarter & Bruno, 
2000). GABA afferents have also been implicated in changes 
in cortical ACh efflux, based on their connections to
cholinergic neurons of the basal forebrain. Previous
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research has revealed a negative correlation between basal 
forebrain GABAergic transmission and cortical ACh release. 
Thus, decreases in GABAergic transmission lead to enhanced
cognitive functioning via increases in cortical ACh (Sarter
& Bruno, 1994).
Benzodiazepine-receptor (BZR) agonists and inverse 
agonists have proved to be quite useful in studying trans- 
synaptic modulation. Trans-synaptic modulation, as defined 
by Sarter and Bruno (1994),- refers to the "effects of 
manipulations of the activity of an afferent neuronal system 
on the excitability of its target neurons." For example, 
this technique has allowed researchers, such as Sarter and 
Bruno, to study the effects of GABAergic modulation on 
cortical ACh. Much of the research contains contradictory 
results, however, the use of these agents has revealed the 
importance of the level of activity in the cortical 
cholinergic projections. Such that they can be used to 
modify cortical ACh to further focus the study of the role 
of ACh in behavioral and cognitive processes (Sarter, & 
Bruno, 1994). BZR agonists and inverse agonists have 
produced significant effects in attention. Specifically, 
infusions of BZR agonists have resulted in impairments in
sustained and divided attention in a similar fashion as
cholinergic antagonists (Sarter, 1994; Sarter, Bruno, &
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Turchi, 1999). These impairments manifest themselves 
during stimulus detection and discrimination thereby 
interfering with previously learned associations (Sarter, 
Bruno, & Turchi, 1999). Both BZR agonists and BZR inverse 
agonists affect cortical ACh efflux and this ability is 
dependent on the activity of the cortical ACh afferents.
For example, BZR agonists decrease cortical ACh efflux while
BZR inverse agonists can increase cortical ACh release.
These findings as well as future research involving BZR 
ligands may pave the way for a deeper understanding of the 
functions of ACh (Sarter & Bruno, 1994). Collectively, the 
research on GABAergic modulation of cortical ACh release has 
suggested further avenues for developing potential 
pharmacological therapies for Alzheimer's disease, in 
addition to the current emphasis in modulating the 
cholinergic system more directly.
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CHAPTER THREE
CLINICAL PHARMACOLOGY
Introduction
Sarter et al. (1996) reviewed research involving the
neuronal mechanisms for determining drug effects on
cognition. Specifically, this paper examined drug-induced 
cognition enhancement and what this means for the future of 
pharmacology. Cognitive psychopharmacology has recently 
gained interest in attentional functions in cognition. This 
new direction is a result of pharmacological research that 
has discovered that certain drugs that are known to produce
effects on learning and memory can also, have an effect on
attentional functions. There is also additional evidence
that claims attentional impairments have a role in the
intensification of cognitive disorders such as dementia. 
Therefore, it is logical to develop drugs that enhance 
cognitive functioning as a means of treatment.
The cholinergic system and its involvement in attention 
has been a key focal point for neuropharmacological 
research. Lesion studies involving this system have led to 
the conclusion that an intact cholinergic system is 
necessary to provide optimal attentional functioning. Based 
on the cholinergic hypothesis of AD, which argues that
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cognitive impairment is the result of cholinergic
hypofunction, cholinesterase inhibitors are- currently used 
in the treatment of AD. Their use is based on the objective 
of enhancing cholinergic neurotransmission through blocking
the breakdown of ACh (Akasofu et al., 2003Barnes et al.,
2000; Liston" et al., 2004; Grossberg, 2003; Richter et al., 
2002; Schatzberg et al., 2001).
There are two major cholinesterases that work to 
breakdown ACh-acetylcholinesterase (AChE) and 
butyrylcholinesterase (BuChE). BuChE is a cholinesterase 
associated with glial cells that represents about 10% of 
cholinesterase activity in the temporal cortex of a normal 
human brain. However, in AD, BuChE activity increases as 
the disease advances while AChE .activity decreases. 
Therefore, the inhibition of BuChE as well as AChE may prove 
to be an important factor in the treatment of AD patients to 
the extent that these treatments prevent the degradation of 
existing ACh (Grossberg, 2003; Liston et al., 2004).
However, the exact mechanism of BuChE is still a mystery. 
Liston et al. (2004) also note that inhibition of BuChE and
AChE may be dangerous. They cite research using AChE 
knockout mice, which are highly sensitive to BuChE 
inhibitors and suggest that such dual inhibition may be
lethal.
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Drug Treatments
Cholinesterase (ChE) inhibitors have reliably been able 
to treat the cognitive and functional problems associated
with AD (Liston et al. , 2004; Rocca et al. , 2002). There
are three ChE inhibitors that are currently most often 
prescribed for AD. They are donepezil, galantamine, and 
rivastigmine. A fourth drug, tacrine, was previously used 
in the treatment of AD, but due to a high occurrence of 
heptotoxicity it is no longer used (Grossberg, 2003; Rocca
et al., 2002) . .
Donepezil (Aricept®) is a piperdine-based compound 
approved by the U.S Food and Drug Administration for the 
treatment of AD in 1997 (Richter et al., 2002; Schatzberg et 
al., 2001). Donepezil selectively inhibits AChE (Barnes et 
al., 2000; Diaz, 1999). Donepezil is metabolized in the 
liver by the cytochrome P450 (CYP450) system and has .two 
active metabolites (Diaz, 1999) . It also has a long half- 
life (approximately 70 hours) compared to the other ChE 
inhibitors. Donepezil also possesses a high affinity with 
plasma proteins (approximately 96% protein bound). What 
this means is that this drug may interfere with other highly 
protein bound drugs taken at the same time (Diaz, 1999; 
Grossberg, 2003, Rocca et al., 2002).
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Rivastigmine is not only an AChE inhibitor but it also 
inhibits BuChE. Rivastigmine is primarily metabolized by 
AChE and BuChE. Thus, rivastigmine is unlikely to interact 
with drugs that are metabolized by the CYP450 system. It 
also has a short half-life (approximately 1-2 hours)
compared to the other approved ChE inhibitors. Previous 
research shows that cognitive improvements related to 
rivastigimine are correlated with the inhibition of AChE■and 
BuChE in AD patients (Grossberg, 2003).
Galantamine is a selective competitive AChE inhibitor. 
In animal studies, galantamine was able to increase ACh by 
37% in the cortex (Barnes et al., 2000). Galantamine is 
metabolized by the CYP450 system. Galantamine has a longer 
half-life (approximately 6 hours) than rivastigmine but 
shorter than donepezil (Grossberg, 2003; Rocca et al.,
2002).
Side Effects
Due to the common mechanism of action of the ChE
inhibitors, they share common side effects. For instance, 
the most common side effects include nausea, headache, 
diarrhea, insomnia, dizziness, muscle cramps, vomiting, 
fatigue, anorexia, depression, abnormal dreams, weight loss, 
extrapyramidal symptoms and frequent urination. The 
exception is rivastigmine, which has a low incidence of the
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aforementioned side effects (Grossberg, 2003, Liston et al., 
2004). This difference is thought to be associated with 
rivastigmine's favored affinity for the G1 globular form of 
AChE instead of G4. The G4 form is found at the presynaptic 
membrane of the skeletal neuromuscular junction. Thus, ChE 
inhibitors that bind to the G4 form may be related to 
symptoms such as muscle cramps and weakness.
In a 6-month comparison of side effects between 
donepezil and rivastigmine, it was found that donepezil had 
significantly more adverse reactions (Grossberg, 2003). In 
contrast, Liston et al., (2004)found that the more selective
AChE inhibitors resulted in fewer peripheral side effects
than the nonselective ChE inhibitors. Liston et al., (2004) 
also argue that rivastigmine's mechanism of action is 
associated with a reduced therapeutic index as well as a
greater occurrence of cholinergic side effects.
Recent studies have linked two of the ChE inhibitors
with sleep dysfunction. Donepezil and galantamine
treatment may reduce rapid eye movement latency leading to 
decreased slow-wave sleep. Insomnia was observed most 
frequently the highest in patients treated with.donepezil. 
However, rivastigmine did not change REM latency and showed
the least disturbance in brain stem functions associated
with sleep (Grossberg, 2003)-.
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Dosing is also related to adverse effects of the ChE
inhibitors. Current practice of administration with the
ChE's is a slow dose escalation. Clinical studies with all
three ChE inhibitors have shown that a slow dose escalation
reduces the number of adverse effects and increases
tolerability (Diaz, 1999; Grossberg, 2003).
Efficacy and Tolerability
Sustained ChE inhibition is a significant contributor 
to the efficacy of the ChE inhibitors.■ Rivastigmine appears
to have the advantage based on its ability to inhibit both 
AChE and BuChE. Research suggests that ChE inhibition by
donepezil and galantamine decreases as BuChE becomes more 
active. In a one year study, rivastigmine significantly 
reduced activity of both ChE's. However, in a study of 
donepezil and galantamine, AChE activity actually increased 
after .6 to 12 months (Grossberg, 2003).
Long-term efficacy tests of donepezil both report 
positive and negative results. . These results may be due in 
part to sample size. In a study by Barak et al. (2001), of
ten AD patients being treated with donepezil for 24 weeks, a 
significant reduction in the behavioral and psychological 
signs of dementia was found. These signs of dementia include 
delusions, irritability, and disinhibition.- Also, all ■ 
patients in the study tolerated the medication (Barak et
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al., 2001). Research using donepezil in open-label 
extension studies, using the Alzheimer's Disease Assessment 
Scale cognitive subscale (ADAS-Cog), has shown that
positive effects of the drug were sustained even after 98
weeks. However, in another study, the same drug was 
unsuccessful at revealing significant cognitive benefits 
compared to placebo. Patients reported a significant 
decrease in loss of activities of daily living in addition 
to improvements and cognitive and behavioral symptoms. 
(Grossberg, 2003; Rocca et al., 2002).
Rocca et al. (2002) conducted a study to evaluate the 
long-term effects of donepezil. This study examined 
outpatients suffering from mild to moderate AD. Cognitive 
impairment was measured using the ADAS-Cog as well as the 
Mini Mental State Examination (MMSE). Activities of daily 
living were evaluated using the Physical Self Maintenance 
Scale (PSMS.) . Two patients dropped out of the study due to 
adverse side effects (severe headaches and diarrhea). 
Donepezil was otherwise well tolerated in the remaining 
patients. Rocca et al. (2002) found that donepezil was 
beneficial to patients in the study suffering from loss of 
memory and other cognitive problems. Significant 
improvements were found on two scales (.ADAS-Cog and MMSE) 
until the 24th week. After the 24-week mark, a gradual
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decline in performance was noted. It was also found that a 
daily dose of 10 mg provided.optimum benefits from the drug.
Results of long-term studies of galantamine are also 
mixed. In a. two-part study of galantamine, totaling 52 
weeks, patients taking the drug for the full 52 weeks 
retained cognitive function compared to, patients who began 
galantamine treatment mid-study. At the end of the study, 
no significant difference was found between the groups. 
However, in a review of ChE inhibitors-, Grossberg (2003) 
states that recent data suggests that the efficacy of 
galantamine may be sustained for up to three years.
In a study of patients taking rivastigmine it was found 
that patients taking the drug showed a greater clinical 
improvement compared to those left untreated. Clinical 
improvement was evaluated using ADAS-Cog scores' as well as 
the MMSE after taking the drug for 1-2 years. Rivastigmine 
also had a positive effect on mood, activity, decreased
l
hallucinations and paranoid behaviors (Grossberg, 2003).
Barnes et al. (2000) conducted a study to evaluate the 
chronic effects of galantamine and donepezil in aged rats 
compared to saline controls. Barnes et.al. (2000) examined 
differences in spatial cognition, hippocampal plas-ticity, 
and nicotinic receptor binding. It was found that both 
drugs increased nicotinic binding in the hippocampus and
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prefrontal cortex, with donepezil having the greatest 
effect. Also, long-term potentiation (LTP) decay was 
extended for both groups. A significant correlation between 
nicotinic receptor number in the hippocampus and maintenance 
of LTP was fotirid. However, no significant effect was found 
using a spatial working memory task (radial arm maze) in 
either drug group. What this research suggests is that 
drugs that increase the number of nicotinic receptors and
have a lower incidence of peripheral side effects, may hold 
the greatest benefit to patients suffering from AD (Barnes
et al., 2000).
Tolerability and satisfaction are also important 
factors to be considered when using ChE inhibitors. In a 
study of tolerability between donepezil and rivastigmine in 
AD patients, it was found that donepezil was better 
tolerated than rivastigmine. Caregivers and physicians also 
preferred donepezil as compared to rivastigmine. This was 
based on the dosing of rivastigmine which requires titration 
and twice daily dosing. In this study, fewer rivastigimine 
treated patients were able to reach or continue the maximum 
approved dosage levels (Hock et al., 2001). In comparison, 
a study of between galantamine and donepezil found that 
patients reported less gastrointestinal adverse effects 
using donepezil. They also reported more satisfaction &
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ease of administration with donepezil (Aarsland et al.,
2002).
AD accounts for 50-60% of dementia cases in individuals
over 65 years of age. Prevalence of AD is positively 
correlated with age (Rocca et al., 2002). Due to these 
statistics, AD research must examine medications that will 
treat various stages of AD. This is where the efficacy and 
tolerability of the ChE inhibitors must be evaluated in 
groups suffering from mild to moderate AD as well as
moderate to severe AD.
Behavioral and Cognitive Effects
Wolfson et al. (2002) conducted a review of published 
randomized controlled trials as well as phase IV open label 
studies. They compared donepezil and rivastigmine' and found 
that both drugs could delay cognitive impairment and 
deterioration for at least 6 months in patients with mild to 
moderate AD. However, after 6 months of treatment, scores on
the ADAS-Cog were found to meet that of controls (Wolfson
et al., 2002).
Gauthier et al. (2000) evaluated the effects of 
donepezil on'behavior in patients suffering from moderate to 
severe AD. Significant improvements in cognition, global 
functioning, and activities of daily living were found while 
using donepezil. Improvement was calculated using such
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measures as the Clinician's Interview-Based Impression of 
Change with caregiver input (CIBIC-plus), Neuropsychiatric 
Inventory (NPI), Caregiver Stress scale (CSS), the MMSE, and 
the Disability Assessment in Dementia (DAD). A significant 
reduction of stress to caregivers was also found in this
study.
Another study with donepezil was conducted by Hampel et 
al. (2002). This study consisted of patients enrolled in a
German post marketing surveillance study. It was found that 
donepezil showed the same improvements in cognitive and 
quality of life in very elderly AD patients as younger 
patients. Cognition was evaluated using the MMSE and quality 
of life was examined on a 3-point scale -improved,
unchanged, worsened (Hampel et al., 2002 ).
Neuroprotective Effects
Dementia is not only associated with Alzheimer's
disease but also with cerebrovascular disease. Based on the
therapeutic effects of AChE inhibitors with patients
suffering from AD, it has been hypothesized that these drugs 
may also help patients suffering from vascular dementia.
This hypothesis is not unreasonable due to the fact that 
many risk factors for AD have a vascular element. For 
instance, 30% of postmortem AD brains have evidence of
cerebrovascular pathology. Thus, the hypothesis is that
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drugs that reduce neuronal damage caused by ischemic events
may be useful in treating AD as well as vascular dementia. 
Other supporting evidence is that ACh is known to enhance 
the effect of nerve growth factor (NGF). Thus the 
neuroprotective role of ACh inhibitors is a valid angle for
AD research (Akasofu et al., 2003).
Akasofu et al. (2003) examined the neuroprotective 
effects of AChE inhibitors using rat cerebral cortex primary 
cultured neurons. Damage was produced by oxygen-glucose 
deprivation on .cortical cell cultures from Wistar fetal 
rats. Lactate dehhydrogenase (LDH) was used as a marker of
neuronal cell damage. Akasofu et al. (2003). found that 
donepezil possessed neuroprotective effects against in vitro 
neuronal cell injury. Donepezil significantly reduced LDH 
release at even its lowest dose. In contrast, galantamine 
and rivastigmine were not successful at reducing LDH even at 
their highest dose.
Other research into pharmacological treatment of AD has 
focused on the involvement of additional systems such GABA. 
Sarter et al. (1996), has used benzodiazepine receptor 
ligands to affect GABAergic transmission thereby influencing 
presynaptic cholinergic activity. The greatest success has 
come from benzodiazepine receptor selective inverse agonists 
that enhance activated ACh efflux and thus improve cognitive
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functioning. The future of cognitive enhancers depends on 
the combined the efforts of a multidisciplinary 
pharmacological approach. Consequently, there are many 
different factors that may mediate the ability of ChE 
inhibitors to enhance cognitive function. It is also very 
clear that more research needs to be done in order to fully
understand the mechanism of action of the ChE inhibitors.
Research also is needed to discover new drugs with less 
adverse effects that are also able to reliably ameliorate 
the problems associated with AD. Research suggests that ACh 
may not be the only neurotransmitter involved in the 
progression of this disease, thus research should further 
examine this possibility. Perhaps in the future
pharmacologists will develop better ChE inhibitors or drugs 
that interact with GABA. Perhaps the neuroprotective 
effects of the ChE inhibitors will provide more answers. In 
the meantime, careful evaluation should be given to each of 
the cognitive enhancers prior to administration. The 
patient's history as well as the progression of the disease 
must also be considered because they appear to play an 
important role in obtaining positive results with these 
drugs.
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CHAPTER FOUR
ANIMAL MODELS OF ALZHEIMER'S DISEASE
Introduction
The development of treatment for Alzheimer's disease 
(AD) has been largely dependent on the use of animal models. 
From the beginning, animal models of AD have been
controversial. Most animal models for AD include modeling 
or recreating the pathological markers which are observed in 
human AD brains,. One of the main critiques of this animal 
model is that these research animals used never actually
have AD itself, whereas in other animal models, the animal
may actually contract and fully develop the disease in 
question (e.g., autoimmune deficiency.syndrome or AIDS). 
However, the use of animal models of AD has led to many 
important discoveries. These discoveries include age- 
related memory impairments in nonhuman primates, a link 
between memory impairment in normal ageing as well as in AD, 
and brain injury-induced impairments in attention which are 
also linked with cognitive deficits (Bartus, 2000).
A current animal model of AD involves the selective
destruction of neurons in the nucleus basalis
magnocellularis (NBM) located in the basal forebrain using 
an immunotoxin, 192 IgG-saporin to target the cholinergic,
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or acetylcholine-containing, cells of the NBM (Wenk, 1997; 
Winkler et al., 1998). The NBM in rats is analogous to the 
human nucleus basalis of Meynert (Fibiger, 1982), which is 
severely degenerated in AD (Au'ld et al., 2002; Braak et al., 
1996; Chiba et al., 1995; Crawley, 1996; Jellinger, - 1998; 
Lowes-Hummel, et al., 1989; Muir, 1997; Nitsch, 1996; Perl,
2000; Samuel et al., 1994; Sarter & Bruno, 1999; Wenk, 1997;
Whitehouse et al., 1981; Winkler et al., 1998). Previous
research suggests that damage to this brain area results in
impairments similar to those observed in Alzheimer's
patients (Muir, 1997). Baxter and Chiba (1999) found that 
the severity of cognitive impairment was highly correlated
with the amount of deterioration of the neurons of the basal
forebrain in rats with selective damage to those cells.
Wiley et al. (1995) developed a method of selectively
damaging the NBM without causing damage to surrounding non- 
cholinergic cells and fibers. This development came in the 
form of an immunotoxin, 192 IgG-saporin (SAP), which has the 
ability to locate and attach itself, to receptors found only 
on cholinergic neurons. This is accomplished by virtue of 
the affinity of SAP for p75''low-affinity neurotrophin 
receptors, which are densely concentrated on the cholinergic
neurons in the NBM in rats. Once SAP has attached itself to
the receptor, it enters the cell and disrupts intracellular
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protein synthesis which ultimately results in cell death.
The result of selectively targeting the cortically- 
projecting cholinergic neurons of the NBM is a profound loss
of ACh in the neocortex similar to that seen in Alzheimer's
disease (Flicker et al., 1985; Wrenn et al., 1998). The
discovery of SAP thus allowed researchers to create a better 
animal model of AD in order to study the pathogenesis of AD ■ 
as well as possible therapeutic approaches.
The development of the selective cholinergic neurotoxin 
SAP has contributed greatly to the understanding of the role 
of ACh in learning, memory and cognition.• Many forms of 
attention, such as divided and sustained attention, have 
been found to be sensitive to selective cholinergic lesions. 
However, there are still aspects of the cholinergic system 
function that remain a mystery. Although many studies have 
used SAP to damage the cholinergic neurons of the NBM, the 
results from these studies have been varied. However, this 
variability may be due to the different means of
operationalizing the psychological construct in question as 
well as the task used to measure it, rather than to 
differential effective use of SAP itself. According to 
Steckler and Muir (1996) there are many promising behavioral 
paradigms that attempt to compare cognitive functioning in 
rodents to humans. However, developing a valid task for
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assessing-cognitive functioning can be quite difficult.
There are many variables to be considered when attempting to 
develop a behavioral paradigm that will provide meaningful 
comparisons between rats and humans. Such variables include 
procedural variables, task complexity, and the dynamics of 
the cognitive processes themselves (Steckler et al., 1996).
It is extremely important that the behavioral paradigms 
used in animal models of AD are- appropriate for the 
cognitive processes in question. For example, there are 
various types and degrees of attention and subtle ■ ■ 
differences in attention may result in very different 
impairments. This is highly relevant since cortical ACh and 
the cholinergic neurons of the nbM have been found to be 
related to attention in humans (Perry & Hodges et al., 1999;
Sarter & Bruno, 1994; Sarter & Bruno, 1999; Sarter, Bruno, &
Givens, 2003). As a result of the success of research 
using the immunotoxin SAP in targeting cholinergic neurons, 
SAP has been the toxin of choice for many lesion studies
related to AD and attention.
As recognized by Steckler et al. (1996), when assessing 
attention, the behavioral task must address the specific 
elements of the type of attention studied. For instance, 
sustained attention tasks must require that the subject 
respond to unpredictable changes in stimulus conditions.
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For these types of tasks the number of stimuli, rate of 
stimulus presentation, and event rate are -crucial to the .
effect of.the task. The 2-choice reaction time task
developed by Pang (1992), an operant 2-choice task developed 
by McGaughy and Sarter (1995), and the 5-choice serial 
reaction time task developed by Robbins (2002), all measure
sustained attention. For selective attention, the 5-choice
serial reaction time task and measures of latent inhibition
are most commonly employed. A disadvantage with these tasks 
is the problem of separating changes in selective attention 
with those of associative learning. For assessing•divided 
attention, the simultaneous presentation of two stimuli is 
used, partly because with successive presentation of stimuli
it is difficult to determine whether the effects are due to
impaired parallel processing or to impaired attention
(Steckler et al., 1996).
Wenk (1997) reviewed the impact that damaging the NBM 
cholinergic neurons has on cognition. Electrophysiological 
studies of SAP lesioned animals suggests that the
corticopetal NBM cholinergic system is involved in the 
control of shifting attention to relevant stimuli. 
Additionally, selective damage to the cholinergic neurons of 
the NBM may impair the ability to focus on and process 
briefly presented relevant sensory stimuli. These
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impairments are consistent with those associated with damage 
to the nbM in humans with AD (Sarter, 1994; Sarter & Bruno,
1999; Sarter, Bruno, & Turchi, 1999).
In addition to studies showing NBM involvement in
attention, other AD animal models have linked cholinergic 
neuron damage caused by SAP to impairments in learning and 
memory (Gallagher, & Colombo, 1995; Wenk, 1997; Wiley et 
al., 1995). First, in order to test the effects of 
intraventricular injections of SAP, where this lesion method 
damages the NBM as well as the medial septal cholinergic 
projections to hippocampus, Wiley et al. (1995) compared 
animals lesioned by intraventricular injections of 0X7- 
Saporin to controls. The behavioral effects of this lesion 
technique were evaluated using step-down and step-through 
passive avoidance tasks, as well as using an assessment of 
open field activity. Wiley et al. (1995). found that SAP 
lesion rats were impaired in learning to avoid shock in the 
passive avoidance tasks. This study suggests that 
cholinergic neurons in the basal forebrain are important for 
memory formation. Results also support that damage to the 
cholinergic neurons of the basal forebrain result in memory 
impairments similar to those found in AD patients (Wiley et
al., 1995) .
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Perseverative Impairments After Nucleus Basalis 
Magnocellularis Lesions
For instance, Wilson and Cook (1995) found'that rats 
with electrolytic NBM lesions made more perseverative errors 
than controls during the acquisition and reversal of a 
visual discrimination task. However, this study involved the 
electrolytic lesion technique which damages brain tissue by 
producing heat. This technique therefore damages not only 
the cholinergic cells of the NBM but also nearby non- 
cholinergic cells and fibers. Because of this additional
damage, perseveration observed in this cannot be
unambiguously linked to cholinergic NBM cell loss, as it is 
possible that these lesion effects were caused by extraneous 
brain damage.
Attention Impairments After Nucleus Basalis 
Magnocellularis Lesions
The construct of attention can be divided into
different sub-types of attention: vigilance or sustained 
attention, and divided attention. Vigilance or sustained 
attention is the ability to resist distractions and continue 
a task set without interruptions. Divided attention is 
reflected in the ability to do more than one task at a time. 
(Muir, 1996; Perry & Hodges, 1999).
Vigilance has been described as the ability and ease
48
with which one can detect and respond to random and
infrequent stimuli (Sarter et al., 2001). Thus, common 
vigilance tasks usually involve discriminating between 
signals and non-signals (Muir, 1996; Sarter et al., 2001). 
Vigilance involves many other processes and cognitive
states, such as arousal and alertness (Perry &' Hodges,
1999).
Many studies have strongly supported cholinergic 
involvement with vigilance. For example, lesions of the 
basal forebrain have led to impairments in sustained 
attention tasks. The degree of impairment has also been 
found to be associated with the level of damage to cortical 
cholinergic inputs. In addition, changes in activity of the 
cortical cholinergic inputs have lead to changes in 
sustained attention performance. Activation of the basal 
forebrain increases activity of cholinergic inputs to the 
cortex and in doing so improves sensory processing as well 
sustained attention performance. Additionally, release of 
ACh in the cortex of animals during a sustained attention 
task is linked to the level of cognitive demand (Sarter et
al., 2001).
McGaughy et al. (1996)examined performance of rats with 
SAP lesions of the NBM in a behavioral vigilance designed to
measure sustained attention. The task included visual
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signals of various, lengths and required rats to discriminate 
signal from non-signal events. Results of this study . 
revealed strong and persistent impairment's in sustained 
attention. Rats with SAP lesions of the NBM were impaired 
at detecting signals but were still .able to correctiy reject 
non-signals. In lesioned rats, cortical AChE-positive fiber 
density was reduced by 29-86%, except for in the basolateral 
amygdala. In most areas, performance was found to be 
significantly correlated with cortical AChE-positive fiber 
density, where lesser density correlated with poorer 
attention performance.
In another sustained attention study, McGaughy and
Sarter (1998) used smaller concentrations' of SAP to. produce
partial lesions of the cortical cholinergic inputs from the 
basal forebrain. Next, they evaluated the. effects of the
cholinesterase inhibitor physostigmine and benzodiazepine 
receptor partial inverse agonist FG 7142. Sustained 
attention was measured in an operant task previously used by 
McGaughy et al. (1996) that required rats to discriminate1 
signal from non-signal events.
In addition to impairments in. sustained attention, rats 
with SAP lesions of the nBM show impairments in divided 
attention. Waite and colleagues (1999) compared the 
behavior effects of SAP on rats using a multiple choice
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reaction time task, water maze, passive avoidance, acoustic 
startle and open field activity. Rats with cholinergic 
basal forebrain lesions had difficulty focusing attention, 
adjusting to changes in timing of trial presentation, and in 
coping with increases in attentional demand. These data 
suggest that damage to the basal forebrain impairs divided 
attention and also causes a more general disruption of 
cognitive flexibility.
Divided attention has also been linked to cortical
cholinergic input. Turchi and Sarter (1997) compared the 
effects of SAP lesions of the corticopetal cholinergic 
neurons of the NBM to sham-operated controls using an 
operant cross-modal divided attention task. The task used 
two-choice conditional visual and auditory discriminations. 
Rats were presented with two conditions of
modality-certainty and modality uncertainty. In the
certainty condition, rats were presented with only a visual 
or an auditory discrimination.' In the uncertainty modality, 
rats were presented with a randomized sequence of all
stimuli of both modalities. ■ A session consisted of 2
unimodal blocks of trials (20 trials each) followed by a 
bimodal block of 60 trials. The NBM lesion group was able 
to perform each discrimination as well as controls in the
unimodal condition, but showed significant impairments in
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the bimodal conditions (Turchi & Sarter, 1997). Results of 
this study suggest that ACh mediates the control and 
distribution of resources used for cognitive processing.• 
Results also reveal a lesion induced decrease in processing 
capacity as well as a preseveration of response accuracy at 
the expense of response latency. The authors hypothesize 
that lesions of the NBM compromise processing capacity by 
making it difficult for rats to process different sets of 
response rules (see also, Muir, 1996). Impairments in
divided attention have also been found to be associated with
aging and neuropathology such as Alzheimer's disease. 
Previous research suggests that impairments in divided 
attention are related to deficits in processing capacity 
(Muir, 1996)
Research with human AD patients have similarly found 
impairments in divided attention. This is particularly 
important because impairments in divided attention have been 
found to be associated with early AD. For example, in a 
dual task experiment, no significant differences were found 
between AD patients and controls when asked to perform the 
two tasks separately. However, when asked to perform the 
two tasks at the same time, AD patients were impaired 
(Baddeley, Bressi, Della Saia, Logie, & Spinnler, 1991;
Perry & Hodges, 1999; Grady, Grimes, Patronas, Sunderland,
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Foster, & Rapoport, 1989; Spinnler, 1991). Grady et al. 
(1989) also found impairments in divided attention among AD 
patient’s. AD patients were, subjected to the Staggered 
Spondaic Word Test, which is a dichotic listening test. In 
this experiment, AD patients were first tested on a test of 
auditory presentations in one ear at a time. Results were 
then compared to the same patient's performance in the 
dichotic listening task where participants were expected to 
divide their attention between two different auditory 
stimuli presented to each ear at the same time. A greater 
impairment was found in AD patients during the dichotic 
listening task than when tested one ear at a time. This 
type of impairment has generally been interpreted as being 
an impairment in divided attention. However, it has also 
been hypothesized to be an impairment of the central 
executive system (Perry & Hodges, 1999).
Impairments in Cognitive Flexibility After Nucleus 
Basalis Magnocellularis Lesions
The impairments in divided attention and the 
observation of perseveration typically observed following 
NBM damage might both, reflect a common underlying impairment 
in cognitive flexibility. Cognitive flexibility has been 
defined, as the ability to shift cognitive set, or to shift
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attention in order to' perceive, process, or respond to 
situations in different ways (Eslinger & Grattan,' 1993'; 
Rende, 2000). Indeed, AD patients show impaired-verbal 
fluency production (Monch et al.,. 1992), impaired 
performance on the Wisconsin Card Sort Task (Paolo, Axelrod, 
Troster, Blackwell, & Koller, 1996), perseveration 
impairments .(Bayles et al.', 2004; Ryan et al.1995; Lamar, et 
al., 1997; Caccappolo-van Vliet et al., 2003), and 
difficulties with changing behavior in response to changes 
in reinforcement contingencies (Bigler et al., 1988). Each 
of these tasks has been linked to the concept of cognitive 
flexibility (Rende, 2000), suggesting.that disruptions in 
this more global cognitive function might account for this 
wide variety behavior impairments.
Animals with NBM damage show impairment in several 
behavioral tasks related to the, construct of cognitive 
flexibility. These tasks include measures of perseveration 
(e.g. serial reversal tasks),-divided attention, configural 
association learning, learning set formation and set
shifting. Again, a common impairment in cognitive
flexibility could account for- these varied behavioral 
impairments following NBM lesions.
Ridley et al. (1985) found significant post-operative
perseveration in marmosets with ibotenic acid-induced
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lesions of the NBM. Ibotenic acid produces -excitotoxic 
brain injury damaging cholinergic but also non-cholinergic 
cells. These animals were tested in a serial reversal task,
where■animals first learn to discriminate between a
reinforced and non-reinforced cue. Subsequently, the 
reinforcement contingencies were reversed such that 
continuing to respond to the previously correct cue (i.e., 
perseverating) disrupted performance. This finding of 
impaired performance in these marmosets suggests a role for 
the NBM in mediating perseveration. However, this argument 
is weakened by the fact that ibotenic acid lesions, like 
electrolytic lesions, produce non-selective damage in
addition to NBM cell loss.
More recently, Ridley and colleagues (Fine et al.,
1997) examined learning impairments, in monkeys, following 
administration of the more selective cholinergic immunotoxin 
SAP. Prior to surgery, monkeys were trained on a series of 
visual discrimination problems. During surgery, monkeys were 
injected either with saline or increasing amounts of SAP 
into the NBM and then presented with a serial reversal of a 
visual discrimination problem. Fine et al. (1997) tested the 
effects of scopolamine on acquisition and reversal of the 
same task. Results indicate a relationship between damage 
to the NBM, amount of cortical AChE, and task performance.
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Lesioned animals treated with scopolamine showed significant 
impairment on acquisition and reversal as compared to 
controls. However, impairments were only revealed in 
animals with significantly large NBM lesions (due to large 
doses of SAP) and AChE loss. These results suggest that.
cholinergic neurotransmission contributes to serial reversal
learning.
Previous research has also shown that NBM lesions in
rats impair the ability to divide attention. Butt and 
Bowman (2002) studied configural association'learning versus 
simple association learning in rats with SAP lesions of the
NBM. NBM lesion rats were able to discriminate between
simultaneously presented black and white visual cues, and 
later were able to discriminate between white and striped 
visual cues. However, performance in these same animals was
impaired when the two visual discrimination problems were 
presented randomly within the same session. These results 
suggest an impairment in the ability to switch between 
strategies for solving different problems. Such an 
impairment might reflect compromised cognitive flexibility 
in general.
Butt and colleagues (Butt, Noble, Rogers, & Rea, 2002) 
found impairments in cognitive flexibility in NBM SAP 
lesioned rats in a negative patterning task. NBM SAP
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lesioned rats and sham-operated controls were tested in a 
simple discrimination task that tests simple association 
learning, and were also tested in a negative patterning 
paradigm that tests configural association learning. In the 
negative patterning task, the separate presentation of a 
tone or light was reinforced. However, simultaneous 
presentation of the light and tone was not reinforced. NBM 
lesioned.rats were impaired during acquisition of the 
negative patterning task, although performance in the simple 
association task was spared. The authors suggest that the 
observed configural association learning impairment may have 
been due to a loss in ability to attend to multiple sensory 
stimuli or to adjust to changes in response requirements 
that vary as a function of stimulus configuration.
In another study, Butt et al. (2003) compared 
performance of rats with bilateral SAP lesions of the NBM 
with control animals in an operant appetitive-to-aversive 
transfer task. In the initial appetitive phase,' rats.were 
trained to press a bar in response to tone presentation in 
order to receive food reinforcement (simple associative 
learning). In the subsequent aversive phase, tone 
presentation signaled impending shock. Upon transfer from 
the appetitive to the aversive phase in the task, animals 
must attend to the change in the predictive significance of
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the tone in order to learn to bar press to avoid shock.' 
Following the shift from appetitive-to-aversive conditions, 
sham operated controls revealed a large positive transfer 
effect; acquisition in the aversive phase was more rapid in 
the transfer group than in a control group tested only on
the aversive task. In contrast, the NBM lesioned rats 
showed acquisition impairment in the aversive phase of the 
appetitive-to-aversive transfer task. ' This impairment was 
specific to the transfer condition, as rats with NBM lesions 
tested only on the aversive task showed .normal acquisition. 
This experiment suggests that NBM lesions disrupt the 
ability to switch between appetitive and avoidance 
strategies upon transfer between the two phases of the task. 
It also suggests that the NBM is important for strategy 
switching behaviors in particular, cognitive' flexibility in 
general.
Previous research using SAP lesions of the NBM have 
found impairments in learning set formation (Bailey et al., 
2003), another index of cognitive flexibility (Rende, 2000). 
Bailey et al. (2003) tested'rats with SAP lesions of the NBM 
on an olfactory discrimination learning set task (ODLS), 
followed by an olfactory discrimination reversal learning 
set (DRLS). Lesions of the NBM impaired•initial acquisition 
of the learning set in the ODLS task, although both NBM rats
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and controls showed evidence of learning transfer from the
ODLS to the DRLS task.
Collectively, these findings suggest that NBM lesions 
cause disruptions in learning, attention, and cognition. 
These varied findings can potentially be related to the 
unifying construct of impaired cognitive flexibility. As 
research on impaired cognitive flexibility in human AD 
continues, and as more researchers test for impairments in 
animal tasks assessing cognitive flexibility following NBM 
damage, this argument may be further substantiated.
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CHAPTER FIVE
THESIS EXPERIMENT
Introduction
Alzheimer's disease (AD) causes severe cognitive 
impairments and is partly characterized by cholinergic cell 
loss in the nucleus basalis of Meynert in humans (Auld et 
al., 2002; Braak et al, 1996; Chiba et al. 1995; Crawley, 
1996; Jellinger, 1998; Lowes-Hummel, P. etal., 1989; Muir, 
1997; Nitsch, 1996; Perl, 2000; Samuel et al., 1994; Sarter
& Bruno, 1999; Wenk, 1997; Whitehouse et al., 1981; Winkler
et al., 1998). This form of dementia affects more than 5
million people in the United States today. A current animal 
model of AD involves the use of the immunotoxin 192 IgG- 
saporin (SAP) to destroy the cholinergic neurons in the
nucleus basalis magnocellularis (NBM), the rat brain
structure analogous to the human nucleus basalis of Meynert 
(Fibiger, 1982) .
Previous research’ using SAP to damage the NBM suggests 
that this brain structure may be involved in supporting 
cognitive flexibility. Impairments in divided attention, 
configural association learning, learning set formation, and 
strategy switching have all been found following selective 
SAP lesions of the NBM (Bailey et al., 2003; Butt & Bowman,
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2002; Butt et al., 2002; Butt et al., 2003; Turchi & Sarter, 
1997). Additionally, previous research using non-selective 
lesion techniques have similarly shown that NBM damage 
impairs the ability to form learning sets. For example, 
Bailey et al. (2001) used quisqualic acid to damage the NBM 
(but also causing damage to non-cholinergic neurons) in 
rats. These animals were tested on a learning set task 
where a common discrimination rule was to be applied across 
a series of novel exemplars. According to Bailey et al.
(2001), the NBM is important in "learning to learn", where 
this type of learning requires higher level cognition.
However, due to the non-selective nature of the lesion 
method used, the resulting cognitive impairments cannot be 
unequivocally linked to NBM damage alone. A follow-up study 
by Bailey et al. (2003) again found learning set formation
impairments in rats with SAP lesions at the NBM, although 
these impairments were transient. Consequently, the extent 
to which the NBM critically contributes to cognitive 
flexibility remains to be determined.
Bigler et al. (1988) note that AD patients have 
difficulty changing behavior in the face of changing 
reinforcement contingencies. Such behavioral impairment can 
lead to response perseveration, a specific form of cognitive 
inflexibility or ridigity. Indeed, perseveration is defined
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as inappropriate persistent responding such that the person 
or animal repeats or fails to inhibit a previous response 
(Bayles et al., 2004; Galdi, 1993). Additionally, evidence 
suggesting that perseveration can result from disrupting 
cholinergic function has been reported in normal humans 
treated with anticholinergic drugs (Bigler et al., 1988).
Animal research further supports the argument that the 
NBM might be involved in inhibiting perseverative behavior. 
In a previous study, for example, rats with electrolytic NBM 
lesions were tested on the acquisition and reversal of a
visual discrimination task. In this task, animals first
learned to discriminate between a reinforced and a non-
reinforced cue, before the reinforcement contingencies were 
reversed such that continuing to respond to the previously 
correct cue (i.e.., perseverating) would interfere with 
performance under the new reinforcement contingency. The 
NBM lesion group made more perseverative errors than 
controls during the reversal of this experiment, suggesting 
that the NBM is normally involved in inhibiting
perseveration under changing reinforcement contingencies 
(Wilson & Cook, 1995). However, the electrolytic lesion 
technique damages not only the cholinergic cells of the NBM 
but also nearby non-cholinergic cells and fibers. Because 
of this additional damage, perseveration observed in this
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study cannot be unambiguously linked to cholinergic NBM cell 
loss, as it is possible that the effects were caused by 
extraneous brain damage in addition to or instead of being 
caused by NBM damage per se.
Ridley et al. (1985) found significant post-operative 
perseveration in marmosets with ibotenic acid-induced 
lesions of the NBM. Although these findings again suggest a 
role for the NBM 'in mediating perseveration, this argument 
is weakened by the fact that ibotenic acid lesions, like 
electrolytic and quisqualic acid lesions, produce non- 
selective damage to cells or fibers in the vicinity of the
NBM.
Cholinergic involvement in perseveration is also 
suggested by pharmacological data from research using the 
muscarinic receptor antagonist scopolamine (Mason, 1983). 
Rats that received injections of scopolamine during 
extinction of an operant task showed greater resistance to 
extinction compared to saline-treated controls. Response 
latencies for the scopolamine-treated rats were
significantly shorter than in controls, suggesting that the 
scopolamine-treated rats were perseverating on the operant 
response despite non-reinforcement.
In the current experiment, the highly selective 
cholinergic immunotoxin SAP was used to lesion the NBM in
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rats before testing these animals in a serial reversal task 
and in a subsequent extinction test. Data from both the 
serial reversal task and the extinction test provided a 
measure of response perseveration and, therefore, cognitive 
flexibility. It was hypothesized that the NBM lesion group 
would acquire the initial operant discrimination between a 
food-reinforced tone (T+) and a non-reinforced light (L-) as 
well as controls. This hypothesis was based on the findings 
by Butt and colleagues (Butt & Bowman, 2002; Butt & Hodge, 
1997) that the NBM is not necessary for learning such simple
associations.
In contrast, it was hypothesized that subsequent serial 
reversal performance would be impaired in the NBM lesion 
group compared to controls. Specifically, across serial 
reversals, it was predicted that the NBM lesion group would 
make more errors across days and would require more days of 
training to reach an a priori performance criterion than
controls.
Additionally, it was hypothesized that there would be 
an interaction effect between type of lesion and consecutive 
reversals on both errors to criterion and days to criterion. 
While the control group (including the sham-lesion and the 
non-operated rats) was expected to show progressive
improvement (i.e., fewer errors and fewer days required to
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reach criterion) across successive reversals, the NBM lesion 
group .was not expected to show such improvement. Because SAP 
selectively targets the cholinergic cells of the NBM while 
sparing adjacent brain tissue (see Wiley et al., 1991), any 
behavioral impairments observed following SAP lesions of the 
NBM can unambiguously be'attributed to the loss of
cholinergic NBM cells. This poses an advantage over
previous research assessing cognitive flexibility in rats 
with non-selective NBM lesions tested in serial reversal
paradigms.
Immediately following completion of four reversals, 
rats proceeded to an extinction phase. Based on the argument 
that NBM lesions cause perseveration, it was expected that 
the NBM lesion group would extinguish the serial reversal 
task more slowly than controls. That is, when the
contingency changed from reinforcement to non-reinforcement 
during extinction training, the NBM lesion group was 
expected to continue to respond due to difficulties altering 
behavior in response to changes in reinforcement 
contingencies. Additionally, it was predicted that there 
would be an interaction effect between type of lesion and 
day of extinction testing on total number of responses.
While the control group (including the sham-lesion and the 
non-operated rats) was expected to extinguish operant
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responding (i.e., to show a progressive decrease in total 
number of responses) rapidly across extinction test days, 
the NBM lesion group was not expected to extinguish as 
quickly.
Methods
Design
The study consisted of three experimental phases: 
acquisition, serial reversal, and extinction. Acquisition 
consisted of operant discrimination between a food- 
reinforced tone (T+) and a non-reinforced light (L-). This 
original acquisition was followed by a reversal phase 
consisting of four serial reversals of the original operant 
discrimination. Finally, the extinction’phase consisted of 
extinction trials, where neither the light nor tone signal
was reinforced.
Acquisition. In the first phase of the study 
(acquisition), a between-subjects two-group design was 
adopted. The independent variable (type of lesion)
consisted of two levels: the NBM lesion and the control 
(including sham-lesion and non-operated rats). During this 
phase there were two dependent measures: total number of 
errors committed prior to reaching criterion and total 
number of days required to reach criterion.
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Serial Reversal. The second phase (serial reversals) 
consisted of four reversals following acquisition. In this 
phase, a 2 x 4 mixed design was adopted. The first 
independent variable (type of lesion) was a between-subjects 
variable (the same as the one manipulated in the acquisition 
phase). The second independent variable (reversal number) 
was a within-subjects variable consisting of four levels.
Each level of this variable referred to one of the four
reversals.. During this phase, two dependent variables were 
measured: errors to criterion and days to criterion.
"Errors to criterion" was defined as the total number of
errors committed prior to reaching criterion for each of the 
four reversals. "Days to criterion" was defined as the 
total number of days required to reach criterion.
Extinction. In the final phase (extinction, which 
immediately followed completion of the fourth reversals in 
phase two) a 2 x 4 mixed design was adopted. Once again, in 
this phase, the between-subjects independent variable, 
namely type of lesion, was Included. The second independent 
variable (day) was a within-subjects variable and consisted 
of four levels which pertained to each of the four days of 
extinction testing. During this phase, one dependent 
variable (i.e., the total number of responses emitted during' 
each day of extinction testing) was measured.
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Animals
A total of 22 male Long-Evans rats (appx. weight 250 g 
upon arrival) were purchased from a commercial research 
animal vendor (Harlan, Indianapolis, IN). Rats were 
individually housed under a 12 hr light/dark cycle with ad 
libitum water and standard rat chow prior to surgical and 
behavioral manipulations.. Prior to surgery and subsequent 
behavioral testing, rats were randomly assigned to one of 
three groups: NBM lesion, sham-lesion, or non-operated 
control. After surgery, rats were reduced to and maintained 
at 85% of their free-feeding body weight in order to 
motivate operant behavior. Rats were fed a restricted amount 
of food immediately on returning to their home cages after 
each shaping or testing session.
Apparatus
Testing was conducted in individual computer- 
controlled, sound-attenuating operant chambers with 
discriminative stimuli consisting of a tone or cue light. 
Reinforcement consisted of the delivery of a sucrose pellet 
(45 mg; P. J. Noyes Co., Lancaster, NH) into the magazine 
located at floor-level along the front panel of the chamber. 
Stimulus onset, lever-press response detection, and 
reinforcement delivery were programmed and controlled via 
computer interface.
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Surgery
Surgical procedures were identical to those used by-
Butt and colleagues (Butt & Bowman, 2002; Butt et al.,
2002). Rats were anesthetized with sodium pentobarbital (55 
mg/kg)' before making bilateral craniotomies above the NBM. 
Craniotomies were located at -0.75 mm posterior to bregma, 
±2.3 and ±3.3 mm from midline. In the NBM lesion group (n = 
11), SAP (concentration 0.4 pg/pl in saline; Chemicbn, 
Temecula, CA) was infused directly into the NBM of both 
hemispheres at -7.8 mm below the skull for the medial sites,
and at -8.1 mm below the skull for the lateral sites. Once'
the cannula was lowered into the brain, there was a 2 min
waiting period to permit the brain to settle around the 
cannula. Following infusions, there was a 3 min waiting 
period to allow for diffusion of SAP away from the cannula 
tip. Rats in .the sham lesion control group (n = 7) 
underwent the same surgical procedure as the NBM lesion
group except that they received intracerebral infusions of 
sterile saline only. Rats were sutured and allowed 10 days 
to recover prior to testing. Rats in the non-operated 
control group (n = 4) did not undergo any surgical
procedures.
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Behavioral Procedure
Rats were first shaped to press a lever in the operant 
chamber for food reinforcement. Rats received three sessions
of lever-press shaping on a continuous reinforcement
schedule in which each session was terminated after 50
reinforcers had been delivered or after 1 hr elapsed,
whichever came first. Rats then received three additional
shaping sessions under a variable interval (VI) schedule of 
reinforcement in which up to 50 reinforcers were delivered 
at intervals ranging from 0 to 80 s, with an average
interval of 40 s (VI-40 s). Each VI-40s session terminated
after 50 reinforcers had been delivered or after 1 hr had
elapsed, whichever came first.
Next, rats were presented with an operant
discrimination consisting of 60 reinforced tone (T+) and 60 
nonreinforced light (L-) trials. Trials were separated by 
an average inter-trial interval (ITI) of 40 s. Training 
continued until rats reached an a priori criterion, defined 
as a discrimination ratio (number of correct responses / 
number of correct responses + incorrect responses) of 80% or 
greater for two days (consecutive or otherwise). Rats then 
proceeded to a reversal of the original discrimination where 
the reinforcement contingencies associated with the tone and 
light were reversed (i.e., T-, L+) . Training continued to
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criteria, when contingencies again were reversed. Rats
underwent a total of four reversals, in addition to the
initial task acquisition.
Upon completing the fourth reversal, rats proceeded to
extinction trials where neither cue was reinforced. Rats
were presented with one extinction session per day for four 
days.
Histology
Following the completion of behavioral testing, rats 
were sacrificed by lethal dose of sodium pentobarbital (80 
mg/kg, ip; Sigma, St. Louis, MO) followed by cardiac 
perfusion first with 0.9% saline, then with 4.0% phosphate- 
buffered formalin, and finally with 5% phosphate-buffered 
sucrose solution. In addition to using chilled perfusion 
solutions, rats' heads were kept on ice throughout perfusion 
to prevent the degradation of the enzyme
acetylcholinesterase (AChE). Brains were then extracted and 
placed first in a phosphate-buffered 10.0% sucrose solution 
for 24 h and then in a phosphate-buffered 25% sucrose 
solution for another 24 h prior to freezing and sectioning 
(60mm) in a cryostat. Alternate sections were then stained 
for AChE using the method of Karnovsky and Roots (1964). 
AChE-stained sections were examined to verify the placement
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and extent of the NBM lesions and to determine the extent of
cortical cholinergic denervation.'
Data Analysis
Acquisition. Acquisition of the initial discrimination
was analyzed by two separate two-tailed t-tests for
independent samples. One testing the number of errors 
committed prior to reaching criterion and one testing the 
number of days required to reach criterion.
Serial Reversal. Serial reversal performance was 
analyzed by two separate ANOVAs' for mixed designs. in
addition, independent-samples t-test were used to test
between group differences on each reversal. The dependent 
measures were the number of errors committed prior to 
reaching criterion and the number of days required to reach
criterion on each of the four discrimination reversals.
Extinction. Extinction data were analyzed by a single 
ANOVA for mixed designs. The dependent measure was the total 
number of responses emitted on each of the four days of 
extinction testing.
A significance level of p = .05 was adopted to conclude 
statistical significance for all analyses.
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CHAPTER SIX
RESULTS
Sham-Lesion and Non-Operated Controls
Data from animals in the sham-lesion and non-operated 
control groups were compared prior to combining these groups 
for subsequent analyses. No between-group differences were 
observed for either the days to criterion or errors to 
criterion measures during acquisition of the original
discrimination, t(9) = -1.348, p > .05, and t(9) = -1.149, p >
.05, respectively.
During reversal training, there was no significant 
between-group (sham-lesion vs. non-operated control)
difference on the number of days to reach criterion, F(l, 9)
= 0.024, p > .05, or on the number of errors to reach
criterion, F(l, 9) = 1.121, p > .05. Although no between- 
group differences were found, there was a significant main
effect for "reversal number" on days to criterion, F(l, 9) =
16.245, p <.05, as well as errors to criterion, F(1
, 9) = 28.937, p < .05, where both measures decreased across
successive reversals. No interaction between "type of 
lesion" and "reversal number" was observed for either days 
to criterion or errors to criterion, indicating that trends 
in performance across the four reversals did not differ
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between the sham-lesion and the non-operated control groups. 
Because no between-group differences were found for both 
days to criterion and errors to criterion, data from these
two control groups were combined. Hereafter, the combined 
group (including the sham-lesion and the non-operated rats) 
will simply be referred to as the control group.
Acquisition
Acquisition of the original discrimination did not 
differ across testing sessions between the NBM lesion and 
control groups (see Figure 1). The results of two separate 
independent-samples t-tests confirmed these observations.
There were no significant between-group differences in the 
number of days required to reach criterion (see Figure 2, 
Part A)), t(20) - .093, p > .05. Additionally, there were 
no significant between-group differences in number of errors 
committed prior to reaching criterion (see Figure 3, Part 
A), t (20) = .027, p > .05.
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Acquisition
Day
Figure 1. Mean (+/- SEM) Percent Correct During the 
Acquisition Phase For Nucleus Basalis Magnocellularis and 
Control Groups in the Serial Reversal Task.
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Days to criterion
12
Figure 2. Mean (+/- SEM) 
During Acquisition (A).
Days Required To Reach Criterion
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Figure 3. Mean (+/- SEM) Errors Required To Reach-
Criterion in the Nucleus Basalis Magnocellularis and Control 
Groups During Acquisition (A).
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Serial Reversal
One animal from the NBM lesion group was dropped from 
the experiment because of scores that were significantly 
different (greater than 2 SDs) from the mean of other 
animals in the NBM lesion group. This animal's superior 
performance may have resulted from an incomplete lesion, 
although existing
techniques in our laboratory are insufficient to quantify 
potential differences in the magnitude of NBM lesions.
Serial reversal performance was impaired in the NBM 
lesion group compared to the control group (see Figure 4). 
Separate ANOVAs for mixed designs on the number of errors 
committed prior to reaching criterion, and on the number of 
days required to reach criterion confirmed this observation
78
Percent Correct for Serial Reversals
Figure 4. Mean ( + /- SEM) Percent Correct Across the 
Four Reversals For the Nucleus Basalis Magnocellularis and
Control Groups in the Serial Reversal Task. The Nucleus 
Basalis Magnocellularis Group Demonstrated Perseveration in 
Reversal 1, Requiring More Days To Reach Criterion Than 
Controls (See Figure 5, Part B ).
7 9
Degrees of Freedom
The assumption of sphericity was not met with either
the ANOVA on days to criterion or the ANOVA on errors to 
criterion. Consequently, Greenhouse-Geisser adjustments 
were applied to within-group main effects and to 
interactions to adjust the degrees of freedom for the 
averaged tests of significance on both of these measures.
Days to Criterion
A significant between-group difference was found for 
the number of days to reach criterion (see Figure 4), F(l, 
20) = 6.318, p < .05. The results of additional independent-
samples t-tests revealed that the main effect for type of
lesion on days to criterion was due to the group difference 
occurring on the first reversal, t(20) = 2.864, p < .05. No 
significant between-group differences were•observed on each 
of the subsequent reversals.
A significant main effect for "reversal number" on
number of days to reach criterion was also found, F(2.154, 
43.084) = 33.682, p < .05, demonstrating a decrease in the
number of days to criterion across successive reversals in 
both groups. A significant "reversal number" by "type of 
lesion" interaction yielded an F(2.154, 43.084) = 4.806, p < 
.05, indicating that performance in the NBM lesion group and 
the control group did not change at the same rate across the
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four subsequent reversals. This interaction reflects a large 
between-group difference in days to criterion observed on 
the first reversal followed by recovery in the NBM lesion 
group (indicated by the small between-group difference in 
days to criterion) on each of the subsequent reversals (see 
Figure 4).
Days to criterion
A R1 R2 R3 R4
B
Figure 5. Mean (+/- SEM)Days Required To Reach Criterion 
in the Nucleus Basalis Magnocellularis and Control Groups 
Across Four Reversals (Rl Through R4) in the Serial Reversal 
Task (B).
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Errors to Criterion
No significant between-group difference was found for
number of errors to reach criterion (see Figure 6), F(l, 20)
= 3.107,. p > .05. A significant main effect for reversal
number on the number of errors to reach criterion was found,
demonstrating a decrease in the number of errors to reach
criterion across successive reversals in both groups,
F(2.108, 42.156) = 24.871, p < .05. The reversal number by 
type of lesion interaction for errors to reach criterion was 
also significant, F(2.108, 42.156) = 3.086, p = .05. A 
large between-group difference in errors to criterion was 
observed on the first reversal followed by recovery in the 
NBM lesion group (indicated by the small between-group 
difference on errors to criterion) on each of the subsequent 
reversals (see Figure 6).
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Figure 6. Mean (+/- SEMj Errors Required To Reach 
Criterion in the Nucleus Basalis Magnocellularis and 
Control Groups Across Four Reversals (R1 through R4) in 
the Serial Reversal Task (B).
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Extinction
One animal was removed from the analysis of extinction 
data because it was inadvertently run on a fifth reversal, 
which may have affected performance during subsequent 
extinction. No significant between-group difference was 
found for total number of responses during extinction, F(l, 
11) = 2.107, p > .05. A significant main effect for 
extinction day was found on the total number of responses, 
F(3, 33) = 9.204, p < .05, where total number of responses 
decreased across successive days. There was no extinction 
day by type of lesion interaction for total number of 
responses, F(3, 33) = 1.833, p > .05, indicating that 
patterns in performance did not differ between the NBM 
lesion and control groups (see Figure 7).
Examination of the extinction patterns in Figure 7 suggests 
that performance in the NBM lesion and control groups did in 
fact differ, but only after the first day of extinction 
training. On Day 1, both groups responded equally, which 
suggested no differences in resistance to extinction. 
Consequently, each day of extinction was analyzed separately 
using independent-samples t-tests.
Independent-samples t-tests for each of the four days
of extinction revealed that the significant between-group 
difference on total number of responses occurred only on the
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second day of extinction, t(12)= 2.817, p <.05, with the NBM 
lesion group making more total responses than the control
group.
0 j------------------------------------------------
12 3 4
Extinction Day
Figure 7. Total Responses During Four Days of Extinction 
of the Previously Reinforced Cues of the Serial Reversal 
Task. The Nucleus Basalis Magnocellularis Group Made More
Perseverative Responses During Extinction Than Controls 
Across Days 2-4 Of Testing, Although Initial Extinction 
Performance Did Not Differ Between Groups.
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Histology
Differences in AChE-positive staining were observed
between the cortices of rats in the NBM lesion and sham-
lesion control groups (see Figure 6). In addition to the 
depletion of AChE throughout the cortex, brains from the NBM 
lesion group showed a loss of AChE-positive fibers and cell 
bodies in the vicinity of the NBM, whereas no such loss was 
found in sham-lesion control brains. Additionally, SAP 
lesions of the NBM did not deplete the hippocampus and 
amygdala of AChE, suggesting that the cholinergic medial 
septal projections as well as the basoamygdaloid cholinergic 
pathways were not damaged by SAP lesions of the cholinergic
NBM.
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Acetylch ol i nesterase
Figure 8. Differences in Acetylcholinesterase-Positive 
Staining Observed Between the Cortices of Rats in the 
Control (A, C, and E) and Nucleus Basalis Magnocellularis 
Lesion Groups (B, D, and F). Note the Depletion of 
Acetylcholinesterase Throughout the Cortex of the Nucleus 
Basalis Magnocellularis Lesion Brain. Brains From the 
NucleussBMagiocellularis Lesion Group Showed a Loss of 
Acetylcholinesterase-Positive Fibers and Cell Bodies in the 
Vicinity of the Nucleus Basalis Magnocellularis Whereas No
Such Loss Was Found in Control Brains.
Control SAP
87
CHAPTER SEVEN
DISCUSSION
Introduction
Lesions of the NBM spared acquisition of the original 
discrimination, impaired subsequent reversal performance, 
and caused prolonged extinction as hypothesized. During 
acquisition, the NBM lesion and control groups did not
differ on the number of errors committed or on the number of
days required to reach criterion. The sparing of
performance in the original discrimination, a simple
association learning task where response contingencies do 
not change (see Pearce & Wilson, 1990; Rescorla, 1972;
Sutherland & Rudy, 1989), suggests that the NBM is not 
necessary for learning in situations where demands on 
cognitive flexibility are minimal. In contrast, on the 
first reversal during serial reversal training, the NBM 
lesion group required more days and committed more errors in 
reaching criterion compared to the control group. Despite 
this initial impairment, the NBM lesion group demonstrated 
recovery on subsequent reversals. Impaired reversal 
performance in the NBM lesion group is argued to result from 
perseveration on the originally correct discriminative 
stimulus, where this perseveration is believed to reflect
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and underlying impairment in cognitive flexibility. During 
extinction, the NBM lesion group made more total responses 
and extinguished responding more slowly than the control 
group. The greater resistance to extinction observed in the 
NBM lesion group is similarly argued to reflect cognitive 
inflexibility expressed as perseveration on the previously
reinforced discriminative stimuli.
Acquisition
Results supported the hypothesis that SAP lesions of 
the cholinergic neurons of the NBM would spare acquisition 
of original discrimination (T+, L-) . The NBM lesion groupf
learned to selectively respond to the reinforced stimulus as
well as controls. These results are consistent with earlier
findings of intact simple association learning in rats with 
SAP lesions of the NBM (Butt & Bowman, 2002; Butt & Hodge, 
1997; Butt, Schultz, Arnold, Garman, George & Garraghty,
2003). In these previous studies, as well as in the 
acquisition phase of the current experiment, the contingency 
between discriminative cues and the availability
reinforcement was unambiguous and unchanging. Moreover, 
these tasks do not require sustained (see McGaughy et al., 
1999; McGaughy & Sarter, 1998) or divided attention (see 
Turchi & Sarter, 1997; Waite et al., 1999), nor do they tax
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cognitive'flexibility. It is argued that NBM lesions did 
not affect performance in the original discrimination in the 
present experiment specifically because this task does not 
place significant demands on attention or require cognitive 
flexibility.
Serial Reversal
When confronted with subsequent reversals of the 
original discrimination, performance in the NBM lesion group 
was impaired relative to the controls as hypothesized. The 
NBM lesion group committed more errors and required more 
days to reach criterion than controls on the first reversal. 
Although the NBM lesion group was impaired on the first 
reversal, their performance recovered and groups did not 
differ on subsequent reversals. Additionally, it was 
hypothesized that on both the errors and days to criterion 
performance measures, there would be an interaction between 
group and reversal number. Specifically, the control group 
but not the NBM lesion group was expected to show
progressively fewer errors and require fewer days to reach
criterion across successive reversals. There was a
significant interaction between group and.reversal number on 
both the days, to criterion and errors to criterion measures, 
although the pattern of this interaction was not consistent
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with the hypothesis. It was hypothesized .that the control 
group would show- progressive improvement (i.e., fewer days 
to reach criterion, and fewer errors prior to reaching
criterion) across successive reversals, while the NBM lesion
group was not expected to show such improvement. Instead, 
both groups improved across successive reversals, with the 
NBM lesion group showing substantial impairments on the 
first reversal followed by a rapid recovery in performance.
Performance in the NBM lesion group suffered only when 
reinforcement contingencies were reversed following the 
unimpaired acquisition of the original discrimination. 
Animals in the NBM lesion group learned to discriminate
between the reinforced and a non-reinforced stimuli
normally, but when the reinforcement contingencies were 
reversed, animals in the NBM lesion group perseverated on 
the previously correct stimulus despite nonreinforcement 
under the new (reversed) reinforcement contingencies. The 
control group, in contrast, adapted their responding to 
these changing response contingencies more readily than the 
NBM lesion group and showed comparatively little
perseveration across serial reversals of the original 
discrimination. These data suggest that NBM lesions disrupt 
the ability to efficiently switch between conflicting ,
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response rules, while sparing the ability to discriminate 
between stimuli in general.
The observation of behavioral recovery during the later 
phases of serial reversal training in the current experiment 
in the NBM lesion group may potentially reflect compensation 
by other neurotransmitter or neuromodulatory systems in 
these brain damaged animals. An alternative interpretation 
of the observed behavioral recovery in the NBM lesion group 
might be that while the first reversal was sufficiently 
challenging, subsequent reversals did not tax cognitive 
mechanisms enough to reveal NBM lesion-induced impairments. 
As normal animals progress through serial reversals, their
performance typically continues to improve with each
subsequent reversal (e.g., Bailey et al., 2003; Bonney & 
Wynne, 2002). In the current experiment, however, control 
animals appeared to reach asymptotic floor levels of 
performance as early as the second reversal, suggesting that 
the cognitive demands of serial reversal may have been 
comparatively low in this task. Consequently, while the NBM 
lesion group was impaired on the first reversal, cognitive 
demands in the task may have been insufficient to reveal 
further lesion-induced impairments as the NBM lesion group 
achieved performance levels equivalent to controls by the 
second reversal. Nevertheless, the behavioral impairments
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observed in the NBM lesion group when reinforcement
contingencies were first reversed demonstrate NBM
involvement in inhibiting perseveration during serial 
reversal learning, and suggest NBM involvement in cognitive 
flexibility in general.
Extinction
The hypothesis that the NBM lesion group would 
extinguish responding more slowly than controls was 
supported. NBM lesions caused response perseveration under 
conditions of extinction, despite the fact that the NBM 
lesion group had previously demonstrated behavioral recovery 
during the later phases of serial reversal training. When 
the contingencies changed to the non-reinforced conditions 
of extinction, the NBM lesion group continued to respond to
the discriminative stimuli longer than controls. This 
evidence of perseverative responding during extinction is 
attributed to an NBM-lesion induced difficulty in modifying 
behavior in response to changes in reinforcement
contingencies.
Both the perseverative responding observed during 
extinction, and the perseveration observed during serial 
reversal training, are argued to reflect a common underlying 
impairment in cognitive flexibility. Together, these
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results strengthen the argument that the cholinergic NBM is 
normally involved in mediating response inhibition (i.e., 
prevents perseveration), and is involved in cognitive 
flexibility more generally.
The prolonged extinction and perseveration observed 
following NBM lesions in the current study are similar to 
findings from previous studies using pharmacological 
manipulations of the cholinergic system. For example, Mason 
(1983) found that rats treated with the'anticholinergic 
muscarinic receptor antagonist scopolamine showed greater 
resistance to extinction (i.e., greater perseveration) in an
operant discrimination than saline treated controls. The 
perseveration caused by the scopolamine-induced compromise 
in cholinergic function mirrors the effects observed 
following NBM lesions in the current experiment.
Conversely, treatment with the cholinergic agonist
physostigmine (an AChE-inhibitor) in the Mason (1983) study 
resulted.in accelerated extinction (i.e., decreased 
perseveration) compared to saline treated controls. These 
data suggest that cholinergic activity is a critical 
component of learning to withhold responding during 
extinction conditions. Together these pharmacological data 
clearly demonstrate cholinergic involvement in mediating 
response inhibition during extinction, an interpretation
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consistent with the findings from the current NBM lesion
study.
Conclusion
To summarize, selective SAP lesions of the NBM spared 
acquisition of the original discrimination as predicted.
This result demonstrates the lack of NBM involvement in
simple association learning, where demands on attention are 
low and where cognitive flexibility is not required to solve 
the task. In contrast, NBM lesions caused perseveration and 
disrupted cognitive flexibility during serial reversal 
discrimination learning; During extinction trials following 
serial reversal training, NBM lesions also led to -
perseveration, where this perseveration is argued to reflect 
cognitive inflexibility.
Cognitive flexibility has been defined as the ability 
to adapt to changing response rules, shift cognitive set, or 
to shift attention in order to respond to situations in 
different ways (Eslinger & Grattan, 1993; Rende, 2000). 
Previous animal research suggests that damaging the NBM 
causes impairments in many of these' abilities. For example, 
selective SAP lesions of the NBM cause impairments in 
divided attention (Turchi & Sarter, 1997; Waite et al.,
1999), configural association learning (Butt & Bowman, 2002;
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Butt et al., 2002; Butt et al., 2003), learning set
.formation, and strategy switching (Bailey et al., 2003). It 
is possible that the impaired performance observed in the 
wide variety of.behavioral paradigms used to assess these 
various abilities reflects a common underlying impairment in 
cognitive flexibility. Results from the current experiment 
similarly can be interpreted as reflecting an NBM lesion- 
induced impairment in cognitive flexibility.
The NBM may participate in cognitive flexibility 
through its influence on the medial prefrontal cortex; this 
brain region receives extensive cholinergic projections from 
the NBM (Mayo et al., 1984). Cholinergic activity in the 
medial prefrontal cortex is critical for normal performance 
in attention demanding tasks (McGaughy et al., 2002; Sarter 
et al., 1997; Sarter et al., 1999), and is involved in tasks 
requiring cognitive flexibility (e.g., Ragozzino, Wilcox, 
Raso, & Kesner, 1999) . For example, previous research has 
shown that temporary inactivation by tetracaine of specific 
subregions of the medial prefrontal cortex impaired learning 
when rats were switched .from a spatial to a visually-cued 
version in a spatial learning task but not when animals were 
tested in either version of the task alone (Ragozzino et
al., 1999).
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Wise and colleagues (1996) argue that the medial 
prefrontal cortex is involved in learning new behavior- 
guiding rules and in rejecting previously acquired but 
currently invalid rules. These authors propose that 
reversal learning and shifting between perceptual dimensions 
or strategies are mediated by the prefrontal cortex (Wise, 
Murray, & Gerfen, 1996) . The medial prefrontal cortex, 
therefore, appears to be involved in a wide variety of 
behavioral tasks requiring cognitive flexibility.
The impaired serial reversal discrimination learning 
and prolonged extinction observed in the current study may 
have been caused by the cholinergic demodulation of the 
prefrontal cortex which results from damage to the NBM.
Other research has shown that damaging only the cholinergic 
projections to the prefrontal cortex impairs the ability to 
form complex, or configural associations (Mayo et al.,
1984), where configural association learning itself 
critically depends on cognitive flexibility (see Butt & 
Bowman, 2002) . Cholinergic modulation of the medial 
prefrontal cortex may therefore represent a critical neural 
substrate supporting cognitive flexibility in general.
The current findings clearly indicate that NBM 
cholinergic modulation of neural activity in the neocortex 
is critically involved in cognitive flexibility. A fuller
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understanding of the neural substrates for this high level 
cognitive function will, of course, require a considerable 
amount of further research. For example, future research 
might examine the specific functions of cholinergic 
modulation of discrete cortical regions, including the 
medial prefrontal cortex, by selectively targeting only 
those NBM neurons projecting to such discrete cortical areas 
using emerging lesion methodologies. Our understanding of 
the role played by ACh released into the neocortex by the 
NBM in learning, memory, and cognition might also benefit by 
considering potential impairments in behavior, as well as 
behaviors unaffected by NBM lesions, in light of the 
relative demands placed on cognitive flexibility by the 
behavioral task at hand. It is argued here that only those 
tasks placing sufficient demands on cognitive flexibility 
will be sensitive to selective SAP NBM lesion effects, while 
behavior in less demanding tasks can be expected to spared 
following these lesions.
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